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ABSTRACT 
PRDM1 is a master transcriptional regulator in multiple cell lineages and it is required for 
the development of many species. However the reason and the mechanisms underlying its 
pleiotropic functions remain largely unknown as the full array of tissues and target genes 
that it controls. Our results indicate a completely unexplored field where to study PRDM1 
regulatory network that is the brain and its most aggressive cancer, the Glioblastoma 
multiforme (GBM). We identified that PRDM1 is expressed in adult neural progenitor 
cells and that it correlates with the maintenance of cellular multipotency, possibly by 
interfering with pro-differentiation pathways (e.g. HIF1α signaling). We generated the first 
genome wide profile of PRDM1 binding in mammalian cells, expanding the pool of known 
direct target genes and providing a new solid ground for mechanistical studies that suggest 
a role for PRDM1 in stable and heritable gene silencing during differentiation.  
Finally we found that PRDM1 expression associates with a specific subtype of human 
GBM called mesenchymal and that it is highly expressed in GBM cancer derived stem 
cells. Consequently we have also exploited the functional relevance of PRDM1 in a 
spontaneous mouse model of GBM related to the human pathology. 
Taken together our data add further to the already established role of PRDM1 as a cell fate 
regulator identifying that PRDM1 is involved in normal and aberrant mammalian 
neurogenesis. We also provided a consistent dataset to functionally and mechanistically 
characterize PRDM1 dependent cell fate transitions.  
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Chapter 1 - INTRODUCTION 
1.1 PRDM transcription factor family 
In complex multicellular organisms, cells – that share identical genome – encounter 
diverse lineage choices: a process that determines cell type specific gene expression 
programs1. Current evidence strongly supports a model where cell fate determination is 
orchestrated by lineage determining regulators and chromatin marks - that may be 
transmitted across cell generations - originally instructed by pioneer transcription factors2. 
These transcription factors can engage nucleosomes and compacted chromatin or may 
function as “placeholders”: in fact they can modulate the local epigenetic state of 
chromatin3 in a way to keep active or silent developmental specific genes.  The aberrant 
expression of such transcription factors often leads to cell transformation linked to an 
inappropriate program of cellular differentiation4. However, relatively few examples of 
such regulators have been identified and little is known about how tissue-specific programs 
are established (review in5). 
In this scenario, increasing evidence suggests, the master regulator PRDM1, and more in 
general the PRDM family of proteins, to act as a key instructive transcription factor 
required for the control of cell-fate determination in developing organisms and to maintain 
tissue homeostasis in many organs.  
The PR (PRDI-BF1 and RIZ)-domain containing proteins (PRDMs) derive the name from 
the firstly identified members: positive regulatory domain I-binding factor 1 (PRD1-
BF1)/PRDM1 and retinoblastoma-interacting zinc finger protein 1 (RIZ1)/PRDM2.  
PRDMs have been described to play critical roles in different kind of developmental 
processes 6 7.  They appear to be highly cell type/tissue specific transcriptional regulators 
using either enzymatic activity towards histones or recruitment of interaction partners to 
modify the expression of target genes. 
	   9	  
PRDM1 was identified and cloned by two different groups almost at the same time8: Keller 
and Maniatis originally identified PRDM1 as a transcriptional repressor of the interferon 
beta (IFNβ) promoter following viral infection of U2OS human osteosarcoma cell-line9, 
while Turner and co-workers identified the mouse homologue by subtractive cloning of 
transcripts that were induced during differentiation of B cell lymphoma 1 line (BCL1) and 
they called the protein Blimp-1 (B lymphocyte-induced maturation protein-1)10.  
The other founding member of the family, the zinc finger gene RIZ1 (or PRDM2) was 
isolated in a functional screening for Rb interacting proteins11 and in the same article, the 
authors recognized the homologous amino-terminal 100 amino acids region shared 
between RIZ1 and the PRDI-BF1/Blimp1. Subsequently, the RIZ1 PR domain peptide was 
used as a query for a Genbank homology search showing that the predicted translation 
product of Mds1-Evi1 locus (also called Mecom or Prdm3, fusing Evi1 gene with what had 
previously considered an independent upstream locus – Mds1) is homologous to the amino 
end of RIZ112. This analysis allowed the identification of the Mds1-Evi1 gene as a PRDM 
gene that normally produces at least two different length products: the PR containing 
MDS1-EVI1 (PRDM3) protein and the PR lacking EVI1 protein.  
The family grew further as additional proteins in vertebrate were identified on the basis of 
the PR domain conserved in mouse, rat and human with a sequence identity reaching 40%. 
This class of genes originated in metazoans and is evolutionary conserved. Gene 
duplication and loss events13 14 have changed PRDMs number among different species. In 
invertebrates, the orthology assignment yielded two genes for nematodes and three genes 
for arthropods, while in vertebrates there are 17 putative PRDM orthologs in primates 
(Fig.1) and 16 putative orthologs in rodents, birds and amphibians, possibly meaning that 
the functional specialization of PRDMs has increased during the evolution15. Moreover 
since no PR peptides were detected in the yeast genome, it’s plausible to hypothesize that 
the PR domain may have evolved as a result of a special need of multicellular organisms. 
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1.1.1 PR and SET domains: analogies and differences 
Using bioinformatics tools, PR domain was shown to share consistent sequence homology 
with SET domain (named after the Drosophila factors Suppressor of variegation 3-9, 
Enhancer of zeste and Trithorax were originally identified) that is characteristic of protein 
lysine methyltransferases16 17 18 19. 
Consequently, PR domain has been considered as a sub-type of SET domain even if it 
diverged from the canonical SET structure.  
The aminoacidic sequence similarity between PR and SET domains is typically around 
20% nonetheless they are distinct because identities within PR domains or within SET 
domains are usually higher than 40%. 
SET domain containing proteins encompass many members that have been structurally 
characterized 20 21 22 23 24 . The catalytic domain is composed of a conserved core SET 
domain, surrounded by a limited set of variable regions (the I-SET and post-SET) that 
form the binding groove for the substrate peptide and the co-factor binding pocket. The 
post-SET (immediately at the carboxyl terminal of core-SET) is a dynamic feature, 
important for the substrate recognition.  
Figure 1. PR-domain containing proteins (PRDMs) family. Figure adapted from Fumasoni et al. BMC 
Evolutionary Biology 2007 7:187. Domain architecture of the human PRDM paralogs. For each PRDM protein, the 
corresponding RefSeq Accession Number and additional names are provided.  
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Unlike SET domain, there is little structural information available for PR domain25 26 and 
significant sequence diversity between the two domains impedes the solution of a 
confident homology model.  
Despite sequence similarity, some key residues are not conserved between the two 
domains: in the SET family, mutations in the conserved H/RxxNHxC motif abolish the 
catalytic activity17. However, all PR domains lack this motif. Conversely, only four 
residues are constant in human PR domains: Gly57, Pro58, Trp98 and Leu136. Of these, 
only Leu136 is conserved in canonical SET domains (Fig.2). 
Moreover, SET domains are primarily found at the carboxyl termini of proteins that 
contain various motifs  (including the chromo domain, A/T hooks, zinc finger, PHD 
fingers and GTP binding motifs), which lack obvious DNA binding ability, whereas PR 
domains (all but PRDM11) are located at the amino-termini of a repeated arrays of 
Krüpple type zinc fingers (C2H2 zinc fingers)19 (Fig.3).  
 
Figure 2. Sequence alignment of the PR domain from RIZ1 and several canonical SET domains. Figure adapted 
from Briknarova K. et al, Biochemical and Biophysical Research Communications 366 (2008). PR-domain from 
RIZ1 and SET domains from SET7/9 (1O9SA), DIM-5 (1PEGA), SET8/PR-SET7 (2BQZA), human euchromatic 
histone methyltransferase 2 (EuHMT2) (2O8JB), Clr4 (1MVHA), and Rubisco large subunit N-methyltransferase 
(LSMT) (2H23C). Sequence homology is highlighted by the default ClustalX color scheme.. RIZ1 residue numbers 
are marked above the sequences. β-strands in RIZ1 that are also conserved in most other SET domains are outlined 
on top. In this diagram, the conserved SET core is purple, N-flanking region is blue, C-flanking region is red and the 
more variable inserted region is yellow. Two motifs that are highly conserved in canonical SET proteins, GXG and 
NH, are framed. Positions that are invariant in human PR proteins are marked with asterisks (*).  
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Taking into account all these features, PR domain seems to be a derivative of SET domain 
as both of them are involved in development, cancer and chromatin regulation but with 
diverse molecular mechanisms. 
SET proteins methylate directly histone lysine residues, this being a post-translational 
epigenetic modification that controls the expression of genes by serving as markers for the 
recruitment of particular complexes that direct the organization of chromatin. For PRDMs, 
the enzymatic activity – postulated for the homology with SET – has been found only in 
few PRDMs: by in vitro methylation assays recombinant RIZ1 and PRDM8 were both 
shown to act as repressive histone methyltransferases by catalyzing the dimethylation of 
lysine 9 of histone H3 (H3K9me2), while PRDM9 was found to catalyze the activating 
trimethylated lysine 4 of histone H3 (H3K4me3)26 27 28. More recently it has been 
demonstrated that PRDM3/PRDM16 double null cells have reduced levels of H3K9me1, 
which is responsible for a decrease of Suv39h-dependent H3K9me3 levels in cell 
Figure 3. Prototype members of the various families of Histone Methyltransferases (HMTs). Conserved 
structural features are indicated according to the legend showed at the bottom.  
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chromatin. This effect compromises the structure of pericentric heterochromatin and the 
nuclear lamina of the cells that then undergo senescence. The authors show that PRDM3 
and PRDM16 are cytoplasmic enzymes but they did not provide direct mechanisms for 
their involvement in the maintenance of heterochromatin and nuclear lamina structure29.  
Comparing SET and PR tridimentional structures, only a cysteine residue (C106) is shared 
between RIZ1 PR domain and SET proteins catalytic domain and the mutation of such 
aminoacid in RIZ1 and in SUV39H1 decreases or abolishes their enzymatic activity 26. 
Nevertheless, it is not conserved among the others PRDM members possibly explaining 
the weak biochemical activity for PRDMs. Crystallization studies have shown that the 
flexible carboxyl terminal sequence in RIZ1 PR domain is necessary for functional activity 
- a property that SET proteins use for substrate recognition - but the exact molecular details 
of the complex between RIZ1 and histone H3 await further structural investigation.  
Although mainly “not catalytic”, all PRDMs are present in chromatin remodeling 
complexes. In fact, as mentioned before, from the structural point of view, PRDM proteins 
have two core domains – the PR domain and a series of C2H2 zinc fingers – and other 
smaller domains that serve as scaffolds for the recruitment of co-factors and enzymes to 
the target promoters in a cell-type and context specific manner. For example, PRDM6 
maintains the proliferative potential of smooth muscle cells through the formation of a 
complex with p300 histone acetyltransferase30 while it co-localizes with H4K20 
methylation in endothelial progenitors31. On the other hand, PRDM5 was found to bind in-
vitro G9a and class I histone deacetylases (HDACs) and to recruit them to the target 
promoters yielding H3K9 methylation and H3 and H4 deacetylation, respectively 32. Some 
PRDM members contain also proline rich domain (PRDM18, PRDM333 and PRDM16) 
through which they bind histone modifiers. 
Growing evidence suggests an important role for Krüpple type C2H2 zinc fingers, 
originally identified as DNA-binding domains, in protein binding34: for example the first 
	   14	  
two zinc fingers of PRDM3 serve for SUV39H1 binding35 while PRDM16 uses them for 
CEBP-β36 and PPR-γ  recruitment 37.  
Functionally, PRDMs are transcriptional regulators that bind target promoters via their 
C2H2 zinc fingers in many developmental contexts38 35 and they are important master 
regulators of different cell-fate transitions. For example, PRDM14 was recently 
demonstrated to be important in the maintenance of human embryonic stem cells39 and 
together with PRDM1 regulate the formation of mouse primordial germ cells40 while 
PRDM3 and PRDM16 are both critical for the early hematopoiesis41 42,43. 
 
1.2. PRDM1 is a master cell fate regulator  
PRDM1 is a prototype of PRDM family because it represents well all of the features 
mentioned above and available evidence suggests an involvement in different tumors.  
PRDM1 is expressed in a variety of embryonic tissues42 and it is highly conserved 
developmental regulator in many organisms. In mammals, as well as in other model 
organisms, PRDM1 has been implicated in a large number of regulatory networks 
suggesting that its function is finely tuned. However the full array of tissues and molecular 
mechanisms regulated by PRDM1 are in need of further investigation and constitute the 
scope of this work.  
PRDM1 knock-out (KO) in mouse is embryonically lethal at day 10.5 of gestation and the 
major abnormalities observed indicate its fundamental role in the specification of 
primordial germ cells (PGCs) other than secondary defects including the formation of the 
placenta, the branchial arches and the loss of integrity of the blood vessels 44. 
Whole-mount in situ hybridization (comparing wild type and KO mice) has been used to 
investigate the role of PRDM1 in the first stages of mammalian development. Surprisingly, 
even though PRDM1 localizes in the region (axial mesendoderm) from which antero-
posterior axis and head structures originate in early vertebrates, the formation of the 
anterior patterning and of the neural crest were unaffected by PRDM1 loss44. This 
	   15	  
observation was unexpected and in disagreement with what has been observed in other 
vertebrates: in fact, in Xenopus and zebrafish (see below), PRDM1 transcript localizes in 
the same structures  (anterior mesendoderm and the prechordal plate) where it is 
functionally active for forebrain and early axis formation45,46. 
Despite largely expressed in many compartments, PRDM1 deficient mice die for placental 
abnormalities and mutant embryos display quite restricted tissue impairments. 
The generation of transgenic mice and derived transgenic primary cells - in which a 
reporter gene (i.e. EGFP, membrane-target Venus)47 was cloned under the control of 
PRDM1 regulatory elements - allowed to recapitulate the dynamic expression of 
embryonic PRDM1 and to overcome the limits of KO mice. This model was widely used 
for the understanding of PGCs specification (below) but also it was adopted for the study 
of other tissues especially for skin epithelial cell lineages. 
In fact, it has been assessed that PRDM1 is expressed in a particular population of 
unipotent progenitors in the skin able to give rise to proliferative cells, which in turn 
differentiate (by repressing c-Myc) into sebum-secreting cells. PRDM1 expressing cells 
are also able to induce and mobilize multipotent progenitors when homeostasis of the 
gland is perturbed 48.  
These findings, coupled with immunohistochemical staining of PRDM1 in epithelial 
tissues, gave the rational to perform conditional deletion of PRDM1 in epidermis49. 
PRDM1 is normally expressed in the granular layer keratinocytes where it regulates 
keratinocyte transition from granular to cornified layer, the components of the barrier that 
protect the organism from the external enviroment. In the absence of PRDM1, the granula 
layer of newborns is expanded and contains abnormally undifferentiated enlarged cells. 
The mice develop big scarring other than spenomegaly and enlarged lymphonodes and die 
around 14 weeks. The observed delay in the differentiation process culminates in an 
abnormal cornified layer and in the hyperkeratinization of the hair follicle infundibulum. 
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In an attempt to understand the mechanisms regulated by PRDM1 in epidermal 
keratinocites, the epidermis of 1-day-old mice (wild type and KO) has been used for gene 
expression profiling. The differentially expressed genes encompass different categories 
involved in metabolism, signalling, structural genes of the cornified layer and carriers for 
membrane trafficking. The search for PRDM1 consensus binding site (as it was identified 
in lymphocytes50) in the KO up regulated genes returned six genes (dusp16, elf5, fos, nfat, 
prdm1 and sprr1a) that were confirmed also in-vivo by Chromatine Immunoprecipitation 
(ChIP). Of particular interest is the regulation of Nfat, which serves for the activation of 
transporters that regulate cellular osmosis and promotes water uptake. The unsuccessful 
down regulation of Nfat in PRDM1 KO mice determines the increased cell size of granular 
layer cells and of corneocytes resulting in the abnormal cornified layer.    
Finally, in order to bypass placental defects PRDM1 was conditionally deleted only in the 
embryo proper, lengthening the lifespan until ED 18.551 and assessing that early lethality 
of PRDM1 null embryos was a consequence of extra-embryonic lineages defects and not 
of endothelial cell defects. 
The rescue of early lethality consented to show that PRDM1 plays essential roles in the 
formation of posterior forelimb, secondary heart field and sensory vibrissae and that in 
general PRDM1 is a transcriptional regulator of signalling pathways important for fate 
decision of multipotent progenitors. 
1.2.1 PRDM1 in primordial germ cells 
The importance of PRDM1 in primordial germ cells (PGCs) formation was delineated 
from single cell gene expression profiling studies 52 53,54 aimed to identify the cell of origin 
of germ cells and the fundamental players of the differentiation process. 
In mouse, and probably in all mammals, the formation of germ cell lineage (haploid 
gametes) is not predetermined at fertilization, but it is initiated in incipient somatic cells 
(diploid epiblast cells) that, under specific signals, partially revert to a pluripotent state and 
escape from the somatic program of differentiation – a process called “epigenesis” 53.  
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There are three principal events that characterize the “epigenesis” program: a) escaping the 
somatic program; b) up regulation of pluripotency associated genes and c) ensuing genome 
wide epigenetic reprogramming (Fig.2) 52. 
PGCs originate from a founder population of proximal epiblast cells encircled by the extra-
embryonic ectoderm (ExE) and the visceral endoderm (VE) in the post-implantation 
embryo. At embryonic day (ED) 6.25, this group of cells is stimulated by morphogens 
(BMP4, BMP8 and BMP2) that are secreted from the ExE and induces the expression of 
the interferon-inducible transmembrane protein (fragilis/mil-1/ifitm3) 55 56. Immediately 
after, some of these epiblast cells start to express PRDM1, which from that point onward 
will characterize the lineage-restricted precursors57. As mentioned above these pluripotent 
epiblasts give rise to both germ cells and somatic cells as it has been demonstrated, by 
lineage tracing experiments, that early PRDM1 expressing cells are positive also for 
mesodermal genes (Hox genes, brachyury-T, Fgf8, Snai1, Mesp1, Sp5) 58.  
During early gastrulation PRDM1 positive cells repress the somatic genes (Hoxa1 and 
Hoxb1) and at ED 7.5 the established precursors of germ cells are a cluster of 40 alkaline 
phosphatase and stella (or small nuclear cytoplasmic shuttling protein/Dppa3/Pgc7) 
positive cells located in the extraembryonic mesoderm55. Finally, these cells proliferate 
further and, at ED 10.5, colonize the embryonic gonads where they will differentiate into 
mature germ cells. PRDM1 positive cells contribute to stella positive cells confirming that 
PRDM1 is the earliest marker for lineage-restricted PGCs (Fig.4). 
PRDM1 mutant embryos are able to form no more than half of the PGCs as compared to 
wild type (WT) mice and moreover these immature cells are not able to efficiently 
proliferate and migrate along the developing hindgut endoderm. 
A detailed analysis done by the laboratory of Mitinori Saitou described the transcriptional 
changes occurring in PGCs at different stages of the maturation process (the initial 48 
hours occurring from ED 6.25 to ED 8.25 with 12 hours of interval) and compared them to 
their somatic or PRDM1 null counterparts54. 
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The first observation made by the authors was that while somatic cells during 
differentiation exhibited a homogenous enrichment of Hoxb1 positive cells and a 
homogenous decrease of Sox2 positive cells, the specifying PGCs (PRDM1 positive) 
transited in a “somatic like” expression pattern (Hoxb1 high and Sox2 low) to then 
specifically revert to the Hoxb negative, Sox2 positive state. Pairwise comparison of 
PRDM1 positive PGCs at different developmental stages demonstrated that the major 
expression level changes were between the passage form Hoxb1 positive PGCs to Hoxb-1 
negative PGCs (E6.75-E7.0) during which the cells up regulate 493 genes (also called 
“specification genes”) and down regulate 330 genes (also called “somatic genes”). The 
“specification genes”, based on Gene Ontology (GO) functional annotation were enriched 
for terms associated with: germ cell development (mainly transcription factors-Prdm1, 
Prdm14, Sox3, Dppa3, Ifitm3, Dnd1, Elf3, Elk1, Isl2, Mycn, Klf2, Smad3, Kit and AP2γ), 
morphogenesis and organism development (Sox2, Nanog, and Epc1). On the other hand 
the “somatic genes” were enriched in cell-cycle regulators (CyclinE1, CyclineD1, Cdc25a, 
Cdc6, Pold2, E2F3, Myc and Cdk2), de novo DNA methyltransferases (Dnmt3a and 3b), 
Uhrf1 that recruits Dnmt1 to the replication foci, histone methyltransferase Glp (Ehmt1) 
and Hox cluster genes other than proteins involved in mesoderm induction and organ 
development. 
In PRDM1 deficient cells many of the “somatic genes” were not correctly repressed and 
many of these showed similar expression levels to the somatic neighbour cells. 
Conversely, PRDM1 deficient PGCs acquire to some extent germ cells proprieties but then 
fail to revert to the pluripotent state meaning that PRDM1 independent mechanisms might 
regulate some of the initial “specification genes”. Thus, the main function of PRDM1 in 
the formation of PGC is the repression of the “somatic program” by the down regulation of 
somatic-mesodermal genes, which include cell-cycle regulators and epigenetic modifiers. 
However, also the activation of the “specification genes” is partly impaired in PRDM1-null 
PGCs, confirming that PRDM1 is the master regulator of the entire process. 
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Germ cells from ED 7.75 onwards are subjected to a global epigenetic reprogramming that 
includes the erasure of the parental imprints, reactivation of inactive X chromosome and 
genome-wide CpG demethylation59 60. The major epigenetic changes involve a global 
reduction of H3K9me2 (the levels of G9a are invariant, but embryonic GLP 
methyltransferase is repressed) and of DNA methylation. The dimethylated H3K9, mainly 
associated with repressed regions on euchromatin, is removed at around ED 8.0 and then 
maintained at constant low level until ED 12.5. At ED 9.5 all the migrating germ cells have 
low DNA mathylation signals, a consequence of DNA methyltransferases loss from the 
nuclei of the PGCs. At ED 8.0 the “maintenance methyltransferase” Dnmt1 is absent from 
germ cells nuclei for the duration of a cell cycle (16 hours) and immediately after also 
Dnmt3b and Dnmt3a, the “de novo methyltransferases”, are absent or expressed at very 
low levels, respectively. Conversely, the levels of H3K27me3 (a more labile marker of 
gene repression in embryonic stem cells) and of H3K4me and H3K9 acetylation (markers 
of gene expression and active chromatin) increase in germ cells. In somatic cells 
H3K27me3 is mainly restricted to the X chromosome undergoing inactivation, while in 
migrating germ cells at around ED 8.5-9.0 large spots of H3K27me3 characterize 
euchromatic regions that subsequently will be covered by hyperactive marks59. 
Interestingly, another PRDM family member  (PRDM14) is part of the “specification 
genes” and has recently been demonstrated to be the key regulator of epigenetic 
reprogramming and reacquisition of potential pluripotency in germ cells PMID61. 
PRDM14-null mice born and develop normally, but they are sterile because of complete 
lack of germ cells. Mutant PGCs failed to activate Sox2 and Dppa3 at the wild type levels 
and they showed also an impaired reduction of H3K9me because GLP methyltransferase is 
not properly repressed. These evidences strongly demonstrate that PRDM14 is responsible 
for the epigenetic reprogramming in germ cells and that two PRDMs are the major 
transcriptional regulators of germ cells formation in mice (Fig 4). 62 63  
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1.2.2 PRDM1 in lymphocytes 
Since PRDM1 was originally isolated in a screening for factors that were induced in B cell 
lymphomas differentiating towards Ig secreting cells, its relevance in lymphoid 
compartment has been investigated by generating conditional mouse models. 
The laboratory of Kathryn Calame has studied extensively the abrogation of PRDM1 in B 
cell compartment crossing PRDM1 floxed mice with transgenic mice that express Cre 
recombinase under the control of CD19 promoter64. These studies confirmed and extended 
previous observations65 66, demonstrating that PRDM1 is the master regulator of 
plasmacell differentiation and it is absolutely necessary for Ig secretion from long-lived 
plasma-cells 67,68. Briefly, in adaptive immunity, the process of maturation of an antigen-
specific B-cell comprises two main processes: the formation, in the germinal centre, of fast 
proliferating cells that undergo class switch recombination and antigen affinity maturation 
and the formation of non-proliferating antibody secreting cells. Interestingly, the choice of 
the activated B-cell fate is determined by the antagonism of two master regulators that 
reciprocally counteract: BCL6 for the formation of the cellular component that will 
Figure 4. PRDM1 is a master regulator of primordial germ cells (PGCs) formation in mouse and PRDM14 is 
required for epiblasts reprogramming. Figure adapted from Nature Genetics 40, 934 - 935 (2008). PRDM1 and 
PRDM14 are fundamental players of germ cells formation in mouse. PRDM1 and PRDM14 are induced in proximal 
epiblats by BMP signals from extra embryonic ectoderm. PRDM1 and PRDM14 serve for repressing the somatic 
program and epigenetically reprogram epiblast cells that will generate the PGCs.  These cell will up regulated germ 
cell (stella or Dppa3) and pluripotency markers (Sox2, Pou5f1 and alkaline phosphatase – Alpl). Afterwards (at 
embryonic day 8.5) H3K9me2 histone marks are erased from these cells, the levels of H3K27me3 increase and 
PRDM1-Prmt5 complex mediate H2A and H4R3 methylation. 
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constitute the immunological memory and PRDM1 for the maturation of the humoral 
compartment that will constitute the long-lived plasmacell in the bone marrow survival 
niches 69,70.  
In particular, PRDM1 is continuously required for the maintenance of plasmacytic 
phenotype likely establishing a transcriptional program that characterize terminally 
differentiated B cells6 by the induction of Syndecan, J chain rearrangement and 
immonuglobulin secretion. 
Moreover, PRDM1 ectopic expression alone is able to force the differentiation of BCL-1 
lymphoma cell line and of mouse primary splenocytes in antibody-secreting cells by 
repressing PAX5, a marker of activated B cells, and allowing expression of XBP-171 72. 
Apparently PRDM1 expression was restricted to B cells compartment since, in 
thymocytes, PRDM1 mRNA was detected at a very steady state level. Nonetheless 
PRDM1 expression is much higher in antigen-experienced cells and the genetic ablation of 
PRDM1 in T cell compartment revealed that it also regulates developmental steps in 
diverse lymphocytic lineages73,74. In fact, these mice develop severe colitis due to an 
altered T cell homeostasis: in PRDM1 conditional KO mice the absolute number of naïve 
CD4+T cells in thymus was decreased while, in response to TCR stimulus, the effector 
CD4+T cells showed a hyperproliferation and hyperactivation (Fig. 5). Furthermore, the 
autoimmune inflammation was, in this work, correlated to an impairment of KO regulatory 
T cells (Treg) in protecting against colitis in vivo.  
PRDM1 is also highly expressed in effectors T helper type 2 (Th2) lymphocytes where it is 
mainly involved in contrasting Th1 response during Th2 lineage differentiation in order to 
favour humoral Th2 responses75.  
Finally, PRDM1 is additionally required for the terminal differentiation of effector CD8+ T 
cells76,77. After virus-specific infection naïve CD8+ T cells differentiate into two kinds of 
effectors, the cytotoxic short-lived effector cells and the cytokine producing effector cells 
that give rise to the memory compartment78. The cells defective for PRDM1 preferentially 
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commit though the memory precursor fate while they were insufficient in clearing acute 
infection. 
As it was highlighted for plasmacell formation, also during T lymphocytes differentiation 
PRDM1 and BCL6 are mutually exclusive cell fate determinants. In fact, in some effectors 
the determination of cell lineage is dependent on the expression of such transcription 
factors: for example in CD4+ T cells, BCL6 stimulate a kind of effectors (called follicular 
helper T cells 79) that help the generation of germinal centre80 while they do not express 
PRDM1, which instead characterizes, at different levels, other effectors (Th1, Th2, Th17 
and Treg)81. Again, in CD8+T, PRDM1 controls the cytotoxic effectors73,74,76 and when 
deleted, the cells express more BCL6 in comparison to the WT cells.  
The dichotomy between PRDM1 and BCL6 in the context of B and T cells is a maintained 
mechanism and PRDM1 seems to be important for cell cycle exit of the cells and for the 
terminal differentiation of specialized effectors.  
Only in innate immunity this rule of thumb seems subverted: in fact, although always 
required for maturation and homeostasis of effector functions, in natural killer 
lymphocytes PRDM1 function is independent by BCL6 repression82. 
 
Figure 5. PRDM1 is a transcriptional repressor important for B an T lymphocytes terminal differentiation. 
Figure adapted from Nature Reviews Immunology 7, 923-927 (December 2007). PRDM1 controls the terminal 
differentiation antibody secreting cells and it maintains the homeostasis of effector T cells. In both cases the effector 
cells require PRDM1 to complete their developmental program. Most effector cells in either lineage are short-lived 
and die through apoptosis. The appropriate transition of activated lymphocytes to short and long-lived effector cells 
requires BLIMP1 function. 
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1.2.3 PRDM1 target genes and mechanism of target regulation in PGC and lymphocytes  
PRDM1 has been extensively studied in germ cells and in lymphocytes but the 
identification of direct target genes was limited by the accessibility of such specific cell 
types that are restricted in number.  Moreover the ectopic expression of PRDM1 leads to 
high citotoxicity. Consequently PRDM1 target genes were often evaluated indirectly as 
well as the molecular mechanisms associated with their regulation. 
In PGCs PRDM1 appeared to be essential for the repression of all the “somatic genes” 
since PRDM1 deficient PGC-like cells fail completely to down regulate them. 
The exact molecular mechanism that PRDM1 uses in PGCs for target genes regulation is 
currently under investigation but a pioneer work58 demonstrated that in germ cells PRDM1 
complexes with Prmt5 – an arginine methyltransferase – and that they direct the 
symmetrical dimethylation of H2A and H4 histones (H2A/H4R3me2s).   
In vitro methylation assay of PRDM1 revealed a strong activity towards H2AR3 and 
H4R3, a modification that was never associated before with the PR/SET domain. 
Interestingly Prmt5, which is a class II arginine methylatransferase responsible for the 
symmetrical NG,N’G-dimethylation of arginine, was highly expressed in PGCs with a 
pattern similar to PRDM1. PRDM1 and Prmt5 co-expressed in the nuclei of germ cells 
between ED 8.5 and ED 10.5 and this time point coincides with the maximal accumulation 
of H2A/H4R3me2s in the nucleus (Fig. 4 and 6).  
Additionally, it has been demonstrated that only when PRDM1 and Prmt5 are coexpressed 
in the nucleus are able to exert their repressive function towards a direct target gene – the 
RNA helicase Dhx38. After ED 11.5, the complex dissociates and Prmt5 shuttle to the 
cytoplasm while Dhx38 is up regulated both in female and male PGCs. 
The authors were able to recognize four PRDM1 consensus binding site in Dhx38 whole 
gene body, and using ChIP experiments they showed that the consensus encompassing 
	   24	  
exon 11 was directly bound by PRDM1-Prmt5 complex in ED 10.5 PGCs and it coincides 
with H2A/H4R3me2s and gene repression (Fig 4). 
This mechanism seems to be conserved from Drosophila to humans. In fact in D. 
melanogaster Capsuleen protein, which is the homologous to mouse Prmt5, interact with 
Tudor in germ plasm. Proteins that contain Tudor domain are able to read the covalent 
modifications imposed by arginine methyltransferases and are expressed also in 
mammalian germ cells. 
Also in seminoma tumors, which are thought to derive from PGCs, the complex between 
PRDM1, Prmt5 and H2A/H4R3me2s is maintained. 
 
 
 
 
The specificity of PRDM1 function in B and T lymphocytes corresponds to a divergence in 
the transcriptional networks that govern the different immunological responses. Hence 
PRDM1 direct target genes and coregulators are often distinct for each specialized target 
cell. 
Figure 6. PRDM1 functional domains. Figure adapted from Current Opinion in Genetics & Development 2009, 
19:379–385. Domain architecture of PRDM1. PRDM1 serves as a scaffold for the recruitment of co-repressor 
proteins and enzymes that catalyze histone tail modifications. PRDM1 contains an N-terminal PR/SET domain, a 
proline/serine rich region and five C-terminal C2H2 zinc fingers. Groucho family co-repressor proteins and LSD1 
interact with the proline/serine rich region during plasma cell differentiation. The five C2H2 zinc fingers of PRDM1 
mediate nuclear localization, DNA binding but also serve as a binding interface for interacting proteins (G9a and 
HDAC2 to some extent). The SET domain histone methyltransferase G9a interacts with the first 2 zinc fingers of 
PRDM1 while HDAC2 displays interacts with both the zinc fingers and proline/serine rich region. PRDM1 interacts 
also with the arginine methyltransferase Prmt5 for the formation of primordial germ cells (PGC) in mouse. 
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Despite different pathways that characterized B and T cells, some functional categories of 
regulated genes are conserved in the processes of PRDM1 in driving the terminal 
differentiation of effector cells: in both cases cell metabolism concentrate the efforts for 
protein production rather than proliferation.  
The first category regulated by PRDM1 is the inhibition of both cellular proliferation and 
survival. In fact, PRDM1 stimulates B cells to differentiate into post-mitotic Ig secreting 
cells and in T cells it regulates the terminal differentiation of effector cells. This function 
comprises in B cells the inhibition of c-Myc gene83, which is a PRDM1 direct target 
gene84, and of E2F172 other than the inhibition of anti-apoptotic factors. We have already 
explained the redundancy of PRDM1 and BCL6 reciprocal inhibition in almost all the 
lymphocytes, but also bcl2a185 – an anti-apoptotic member of the Bcl2 family – is down 
regulated in both the lineages. Even if direct evidences of PRDM1 binding are not 
provided, it has been demonstrated that bcl2a1 is induced in PRDM1 deficient Th1 cells. 
This effect may account for the accumulation of CD4+T cells in the periphery since these 
cells are more resistant to in-vitro cell death after cytokine withdrawal74. Finally, the pro-
proliferating gene Id386 is expressed in the subsets of effectors in which PRDM1 is absent: 
in germinal center B cells72, in follicular helper T cells80 and in PRDM1-deficient CD8+T 
cells76.  The repression of Id3 in short-lived effector CD8+T cells has been recently 
demonstrated to be important for the cells to switch between programmed cell-death and 
memory phenotype. 
The second class of target genes that is functionally important is the induction of the 
secretory machinery: the Ig for B cells67 and the cytokines for T cells87. In B-cells the 
genes responsible for protein synthesis and secretion are regulated by Xbp1 gene, which is 
positively associated with PRDM1 transcription in gene expression profiles of splenic B-
cells88. Nevertheless the molecular mechanism of such regulation is currently uncertain 
(maybe dependent on Pax589). In T cells the same mechanism appears much more clear 
and it involves the repression of IL2 90-92. PRDM1 (itself induced by IL2 but with a slow 
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kinetic74) represses IL2 both directly and indirectly by repressing Fos (a part of AP1 
activator complex) possibly contributing to regulatory T cell function in vivo. 
The last important category that is controlled by PRDM1 in lymphocytes is the repression 
of the activated effector phenotype: the germinal center B cells and the Th1 cells. Direct 
targets for silencing the “B-cell program” are: Pax593, class II transactivator (CIITA)94,95 - 
required for MHC class II expression in antigen presentation - and Spib gene72. PRDM1 is 
also promoting the polarization of Th2 lineage (that has humoral characteristics) opposing 
the expression of three genes important for Th1 differentiation75: INF-γ gene that is 
directly bound by PRDM1 in a region up-stream to the promoter characterized by 
H3K4me3 in Th1 and H3K27me3 in Th2 and T-bet gene that is the principal regulator of 
Th1 sub-population as it rapidly induces IFN γ and BCL6. 
Transcriptional regulation of target genes is achieved when PRDM1 binds the DNA via 
two of its five zinc-fingers 96. Attached to a specific sequence of DNA – similar to that of 
interferon regulatory factor (IRF) 1 and IRF2 - it acts as bait, recruiting co-repressors 
complexes97 (Fig.6). 
PRDM1 represses mouse c-Myc promoter by directly recruiting HDAC1/297 through two 
association domains: one located within residues 557 to 715 and the other located within 
the proline-rich domain. Histone deacetylation increases the net positive charge of the 
histones, presumably rendering them more effecting in associating with negatively charged 
DNA to form a more compacted chromatin structure that results in gene repression98. 
PRDM1 causes a deacetylation of histone H3 in the region of c-Myc promoter and the 
treatment with HDAC inhibitor tricostatin A abrogate c-Myc repression in co-transfection 
assay97. 
Subsequently it was demonstrated that PRDM1 is able to bind a heterologous test promoter 
and to recruit – by a repression domain mapped between 331 and 398 aminoacids – the co-
repressor proteins of the Groucho family (in particular hGrg, TLE1 and TLE2). 
Interestingly the same repression domain was discovered to be necessary for PRDM1 
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induced apoptosis in immature B-cells99 and it contains two proline rich sequences highly 
conserved between human and mouse homolog proteins (hence the same region that 
mediate HDACs recruitment for c-Myc repression). Moreover, HDAC2 interacts with 
PRDM1 both indirectly by associating with Groucho proteins and directly through the 
association with PRDM1 zinc-fingers97, so PRDM1-HDACs-Groucho might cluster 
together in repressor complexes (Fig. 6). 
The repressive function of PRDM1 was firstly discovered for its capacity to inhibit human 
IFNβ transcription after viral infection9. The mechanism of IFNβ repression requires the 
binding of PRDM1, which directly recruits the lysine methyltransferase G9a able to silence 
the target promoter causing H3K9me2 38. In this case the methylation of IFNβ promoter is 
strictly dependent on the functional activity of G9a that is recruited by PRDM1 by using its 
zinc finger region38 (even if another work reports the binding also through the proline rich 
domain100). 
More recently the histone demethylase LSD1 has been linked to PRDM1-mediated target 
repression in plasmacell. In fact, it has been demonstrated that they interact through the 
proline rich domain and that they colocalize in the nucleus and in the binding region of the 
target promoter (CIITA). LSD1 depletion leads to a decrease of IgM secretion and to an 
increase of H3 acetylation, H3K4me2 and H3K4me3 levels in CIITA promoter 
determining gene derepression100. Nonetheless LSD1 knockdown did not affect H3K9me2 
level suggesting that more factors can act in concert to establish dynamic repressive 
machinery orchestrated by PRDM1 in the B-cell epigenetic program (Fig. 6). 
1.2.4 PRDM1 in neural development 
PRDM1 homolog has been extensively studied in zebrafish45,101 where it localizes in the 
areas of the developing forebrain - the leading anterior mesendoderm and prechordal plate 
– other than in a variety of other tissue precursors: slow muscle precursor cells; otic 
vesicle; the branchial arches and unidentified cells of the central nervous system.  
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In particular, PRDM1 during zebrafish development gradually distributes in the signalling 
centres of neural commitment and at midgastrulation its expression marks the boundary 
between neural and non-neural ectoderm101,102. Here it plays an important role for the 
specification of different cell types such as neural crest (NC) cells, Rohon-Beard (RB) 
sensory neurons and the neural crest derived craniofacial skeletal elements. 
In vertebrates, NC cells are a transient embryonic population that arises from the dorso-
lateral edge of the neural plate and migrates to differentiate into different specialized 
nervous cells  (neurons, glia of the peripheral nervous system, melanocytes, cartilage and 
bones of the face). Critical transcription factors induced signalling (belonging to BMP, 
Wnt and FGF families) between the neural and non neural ectoderm are needed for cell 
fate acquisition103. From the same region also RB non-migrating sensory neurons originate 
and in the dorsal spinal cord they mediate the mechanosensory touch response and remain 
in the central nervous system104. 
In zebrafish, the specification of different cell types seems to be governed by BMP 
gradient along the embryo that induces PRDM1 expression in different cell compartments 
at the neural plate border105-108. Different studies have defined that PRDM1 is involved in 
the development of both NC cells and RB neurons109,110. In particular PRDM1 is 
transiently expressed in the cells at the neural plate border from where NC cells and RB 
neurons arise but not in the developing cells. Genetic screenings of ethylnitrosourea (ENU) 
mutagenized zebrafish identified two similar phenotypes associated with PRDM1 
impairments: the u boottrp39 (ubo) and the nrdm805 narrowminded (nrd). The major 
abnormalities observed in ubo affect the differentiation of myoblasts into slow muscle 
fibres111,112, the formation of pectoral fins113 – the equivalent of vertebrate forelimbs – and 
the specification of neuronal precursors109. The origin of these defects was determined by 
two point mutations in PRDM1 ortholog, which impair the DNA binding ability of the 
protein. The Ubo mutants display a reduction in the levels of sna2 – a marker of pre-
migratory NC cells – and later on, they show developmental impairment in the 
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specification of NC derivatives: the cells of the cranial trigeminal ganglia (NC origin) were 
smaller and unable to specify in the correct ganglia neurons, the dorsal root ganglia - 
composed by sensory neurons (NC origin) normally organized in ordered segments along 
the spinal cord - was also defective; and finally the mutants have a reduced number of 
melanocytes (NC origin). Also RB sensory neurons fail to specify. 
Interestingly the ectopic expression of PRDM1 mRNA into the fertilized eggs of mutant 
embryos did not rescue completely the phenotype, which resulted in a supernumerary RB 
cells, without any significant change in the NC numbers. This observation helps in 
defining the pathway of neural specification in zebrafish, where PRDM1 ortholog, after 
BMP signalling, is required for the commitment of neural progenitor cells (of both NC 
cells and RB neurons) that by default differentiate into RB sensory neurons and that only 
in the presence of a correct notch-delta signalling are able to specify also in NC cells.  
At the same time another group identified the narrowminded (nrd) mutant zebrafish in 
which neurogenesis and neural crest formation were affected110. Also in this case a point 
mutation hits PRDM1 ortholog, causing a null product completely lacking the zinc fingers 
domain. The mutant nrd failed to form RB sensory neurons while NC cells were present 
early during embryogenesis but then compromised in the ability to differentiate in NC 
derivatives. Contrary to what observed in the previous work, this time the authors were 
able to phenocopying nrd defects by using morpholino depletion and to rescue the 
phenotype by using misexpression of PRDM1. This discrepancy is attributed to the 
different effects of the mutations occurred. In fact, nrd appears to be a null allele, while 
ubo is more likely a hypomorfic allele with a less severe phenotype. These experiments 
suggest also that different PRDM1 levels - from BMP signalling - are needed for 
specifying RB sensory neurons (low levels) and NC cells (high levels). 
A more detailed view of PRDM1 in the nascent lateral border of the embryo would be 
needed to understand if NC cells and RB sensory neurons are really arising from the same 
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PRDM1-positive precursors or if NC cells are initially responding to PRDM1-independent 
signals.  
PRDM1 expression has been found also in the neural plate of Xenopus embryos114 
showing many analogies with zebrafish neural development.  
1.3. Mammalian neurogenesis 
Since our data drove the development of experimental efforts for dissecting the role of 
PRDM1 during adult brain homeostasis, we will briefly introduce some background 
notions about neurogenesis during development and in adult organisms. 
During embryogenesis a portion of the ectoderm specifies to become neural ectoderm. This 
region of the embryo is called neural plate and will form the neural tube from which brain 
and spinal cord (the components of the central nervous system) originate.  
In the developing cerebral cortex, the original neural tube is lined by a ventricular zone, 
composed of a single layer of rapidly dividing neural stem cells called neuroepithelium 
(also known as germinal epithelium). The pseudostratified appearance of the 
neuroepithelium is due to the so-called “nuclear migration” of the neural precursors - 
rapidly dividing stem cells – that extend from the apical to the basal surface of the cortex, 
but have nuclei at different height accordingly with the cell-cycle phase in which they are. 
Around ED 9-10 neuroephitelial cells start to acquire features of glial cells (they are called 
radial glial cells): they are lengthening the radial processes along with the thickening of the 
cortex and they begin to express astroglial markers such as astrocyte-specific glutamate 
transporter (GLAST), brain lipid-binding protein (BLBP), Tenascin C (TN-C), 
intermediate filament proteins (nestin, vimentin) and glial fibrillary acidic protein (GFAP). 
Moreover these neuroephitelial cells begin to make astrocyte-like specialized contact with 
endothelial cells of the developing growing vasculature. 
It is now widely accepted that these glial cells are effectively the neural stem cells that 
undergo distinct mode of cell division in order to generate all the cell types that constitute 
the central nervous system (CNS). From this point onward the cells proliferate 
	   31	  
asymmetrically to maintain the undifferentiated population – that remain in the ventricular 
zone - and to produce a more committed daughter cell that could be a post mitotic neuron, 
which migrates radially, or an intermediate progenitor with more restricted developmental 
potential that populate the embryonic sub-ventricular zone. Consequently during 
embryogenesis radial glia can either work as scaffold of fibers for migrating neurons or 
can itself divide and translocate to the cortical plate and differentiate in more specialized 
cell-types. 
After birth the majority of radial glial cells convert into astrocytes, while a small 
population maintain the contact with the ventricular surface and continue to function as 
neural stem cell in the neonate. 
In the last decades, it has been demonstrated that neurogenesis persists also in postnatal 
and adult brains in two different districts: the subventricular zone (SVZ) in the walls of the 
lateral ventricles and in the subgranular zone (SGZ) of the dentate gyrus of the 
hippocampus115-117. More recently a large number of proliferating cells have been found 
also in the region between the hippocampus and the corpus callosum118. The major 
contribution to the field has been done by the usage of bromodeoxyuridine (BrdU), a 
nucleotide analog, as a lineage tracer through which continuous neurogenesis has been 
visualized in mammals, including humans117,119. 
The SVZ contains quiescent neural stem cells - also known as B cells - that resemble radial 
glial properties (retain apical-basal polarity and are part of the ventricular epithelium) and 
that can give rise to actively-dividing progenitor cells (called C cells), which in turn 
differentiate in neuroblasts (A cells). These neuroblasts migrate along the rostral migratory 
stream (RMS) to the olfactory bulb (OB) through chain migration and differentiate into 
local interneurons with specialized functions in olfaction.  
The SGZ instead produce neurons with specialized function for learning and memory. It 
contains quiescent neural stem cells that divide asymmetrically to generate more 
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committed progenitor cells (type 2 cell), 120which in turn differentiate into glutamatergic 
dentate granule cells121. 
Neural stem cells (NSCs) can be separated from the other neural components and cultured 
in-vitro by using the neurosphere assay122,123, which consists in the continuous exposure of 
neural cells to mitogens in a serum-free medium. These conditions – adopted also for non-
neural tissues such as the mammary epithelium and the cardiac muscle123 - ensure that only 
neural stem cells and undifferentiated progenitors will be able to proliferate in-vitro 
whereas all the other cell populations will extinguish in culture. The proliferating cells 
detach from the plate and form a sphere, which contain only a small fraction (10-50%) of 
neural stem cells while the rest undergoes spontaneous differentiation. Repeated cycles of 
spheres dissociation and replating ensure a progressive enrichment and expansion of the 
neural stem cells in culture, decreasing the presence of nonstem progenitors that have 
limited replication ability. 
The direct isolation of neural stem cells from fresh tissues through the identification of 
specific cell surface markers and fluorescence-activated cell sorting (FACS) has also been 
intensively investigated. The surface antigen CD133 – a five-transmembrane protein also 
known as prominin-1 – is a marker for neuroepithelial cells other than other adult stem 
cells (hematopoietic, liver)124,125. Mouse and human fetal brain NSCs isolated with 
antibodies against CD133 are able to self-renew and to differentiate into neural cell 
types126,127. Other antigens used to separate NSC and radial glia from more differentiated 
cells were: the carbohydrate moiety CD15 (also known as stage-specific embryonic 
antigen – SSEA1 – or LeX) alone128,129 or in combination with CD184 (a G protein-
coupled receptor)108, and CD24, a cell adhesion molecule130. In addition, NSCs and neural 
progenitors have been isolated from dissociated human brain cells by using genetic 
promoter-reporters of NSC specific markers131,132 Anyway selective markers to 
discriminate neural stem from neural progenitor cells are still missing. 
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In normal conditions adult neurogenesis is restricted to neurogenic areas in response to 
physiological and pharmacological stimuli. Alternatively different kind of injuries may 
activate adult neurogenesis like psychiatric diseases, stroke, neurodegenerative disorders 
and cancer. Therefore understanding the mechanisms of NSCs self renewal and 
differentiation is extremely important since they can be used in clinics to treat impaired 
tissues. 
Autocrine and paracrine impulses activate intricate signalling pathways, characterized by 
the expression of specific transcription factors, under which NSCs are able to proliferate or 
to become a specialized cell of the CNS. Four networks are mainly involved in self-
renewal and differentiation of NSCs: a) the Notch signalling; b) the Wnt/β-catenin 
pathway; c) Sonic hedgehog-Gli signalling and d) growth factors (FGF and EGF) 
signalling.  
Moreover embryonic and adult NSCs are characterized by the expression of SOXB1 
factors (Sox1, Sox2, Sox3). In fact, it has been demonstrated that SOXB1 mutants have 
defects in brain development133-135 and, both in-vivo and in-vitro, Sox2 and Sox3 
expression correlate with proliferating cells 136,137. Also, BMI-1, a polycomb family 
transcriptional repressor is fundamental for the maintenance of NSCs and progenitors by 
silencing the cyclin-dependent kinase inhibitors - p16Ink4 and p19Arf  - and p21-Rb 
pathway138,139. The pathway that is mainly involved in NSC maintenance and proliferation 
is the Shh-Gli signalling pathway and its direct effectors Gli-1, Gli-2 and Gli-3 140. 
Conversely Notch and Wnt signalling pathways are involved both in neurogenesis and in 
differentiation signals.  The activation of Notch cascade determines the induction of 
diverse effectors (Hes1, Hes5, C-promoter binding factor1 (CBF1/RBP-J) and Musashi-1) 
that are involved in self renewal activity in both embryonic and adult stem cells. Following 
the interaction between Notch and its ligands (Delta and Jagged), the intracellular domain 
of Notch translocate to the nucleus where it complexes with CBF1/RBP-J and activates 
Hes1 and Hes5 that inhibit neural differentiation of NSCs during development141,142. 
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Moreover Musashi-1 reinforces the effect of Notch signalling by inhibiting its target 
mNumb143. Nonetheless Notch can also trigger the progression of neurogenesis. In fact, if 
expressed at low levels, Notch is able to up regulate the basic Helix-Loop-Helix (bHLH) 
factors such as Neurogenin2 (NGN2) and Mammalian achaetescute homolog1 (MASH1) 
that promote neuronal differentiation144.  
The Wnt signalling pathway has been demonstrated to be relevant both in hippocampal and 
olfactory bulb neurogenesis and to promote the proliferation of adult NSCs145. However 
the Wnt signalling is able also to activate NeuroD1, a pro-neurogenic basic helix-loop-
helix (bHLH) transcription factor, required for the formation of neurons146.  
The early differentiation of NSCs is triggered by lineage-determinant transcription factors 
that make the cells to commit through a more differentiated progenitor and to loose 
multipotency.  
The forced expression of mammalian achetescute homologue (MASH1) in neural crest 
stem cells induces morphological differentiation and expression of neuronal markers147,148 
such as anti-proliferative transcription factors (PHOX2a and cycline-dependent kynase 
inhibitor p27) and pro-neuronal proteins (Neurogenin-1 and NeuroD)148,149. 
Again, PAX6 activates a cascade of factors that are negative regulators of the cell cycle 
and promoters of the neural cell-fate such as NGN2, which in turn represses SOXB1 group 
while it up-regulates HES6.2 a repressor of the Notch signalling150,151. NGN1, another 
important pro-neuronal factor, makes the progenitor cells to escape from the differentiation 
in other lineages by sequestering a CREB binding complex, called mothers against 
decapentaplegic homolog 1 (CBP-SMAD1), from the promoters of astrocytes promoting 
genes and by inhibiting signal transducer and activator of transcription-3 (STAT3) 
necessary for gliogenesis152. STAT3 and SMAD1 instead are the up stream signalling 
factors153,154 that activate the transcriptional expression of glial proteins such as (GFAP), 
OLIG-1 and OLIG-2154. 
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Beside the well characterized pathways, many others remain to be elucidated. Quite 
recently it has been assessed that different members of the PRDM family are expressed in 
diverse areas of the developing mammalian brain and are regulated by the Notch 
signalling155. In particular PRDM8 was shown to be associated with Notch-Hes signalling 
down regulation in post-mitotic neurons while PRDM16 rapidly increased together with 
Notch-Hes stimulus in neuronal progenitor cells.  Since in zebrafish PRDM1 homolog 
enable Notch-bHLH signalling to specify primary sensory neurons and that its expression 
has not been evaluated in adult mouse brain, we cannot rule out the possibility that 
PRDM1 might control neurogenesis also in complex organism and this study argues in 
favour of this hypothesis. 
1.4. PRDM1 in tumors 
PRDMs also play a role in human cancer, where they have been mainly characterized as 
tumor suppressor genes156. 
In tumors different mechanisms, other than gene inactivation and protein stability can 
interfere with PRDM protein function. Remarkably, both transcriptional repression ability 
and tumor suppressor role of various PRDM proteins, rely on an intact PR/SET 
domain12,157,158 and, in human tumors, naturally occurring truncated isoforms of some of 
the PRDM gene family proteins have been identified so far, in which the PR domain is 
disrupted159,160. 
However, although the expression of these alternative isoforms has been linked to 
oncogenesis of multiple tumor types, the function of the PR domain has not been clearly 
defined161,162. 
Evidence exists for PRDM1 to act as a putative tumor suppressor: a) PRDM1 directly 
represses c-Myc, which is frequently de-regulated in B cell tumors83; b) the ectopic 
expression of PRDM1 is toxic in multiple cell types leading to apoptosis in lymphoma cell 
lines99; c) the genomic region where PRDM1 gene resides – on chromosome 6q21-22.1 – 
is frequently deleted in several tumors including in B cell lymphomas 65 and d) PRDM1 is 
	   36	  
mainly known as a transcriptional repressor interacting with different co-repressor proteins 
such as G9a, HDAC2, PRMT5 and LSD1163. 
Indeed, experimental indications agreed with the idea that PRDM1 is a candidate tumor 
suppressor at least in diffuse large B cell lymphoma (DLBCL). 
DLBCL, the most common subtype of non-Hodgkin’s lymphoma, is a genetically and 
clinically heterogeneous disease that - based on gene expression profiling - has been 
classified into three different subsets which resemble the different stages of B cells 
differentiation: the germinal center B cell-like (GCB) DLBCL; the activated B cell-like 
(ABC) DLBCL and primary mediastinal large B cell-like lymphomas164.  
The attempt to identify new genetic lesions that characterize the different sub-types of 
diffuse large B cell lymphoma (DLBCL) brought to the identification of diverse 
inactivating mutations (in both the alleles) in PRDM1 gene. In particular, PRDM1 
mutations were confined to the ABC subtype in 24% of the cases165,166 and in the 77% of 
ABC-DLBCLs PRDM1 protein was not expressed at all, suggesting an alternative 
mechanism – other than mutations – of protein inactivation.65. The spectrum of the 
identified mutations in PRDM1 was very variegated ranging from point mutations 
(nonsense, missense, splicing aberrations) to large intra-chromosomal rearrangements 
while no mutations were found in GCB DLBCL subtype.  
Furthermore, ABC-DLBCL displays a constitutive active NF-kB pathway necessary for 
survival and resistance to chemotherapy treatment167-169 and it is the most aggressive type 
of DLBCL with poor clinical prognosis. 
Recently two studies170,171 definitely demonstrate that PRDM1 is a tumor suppressor in the 
development of ABC-like DLBCL and highlighted the interplay between PRDM1 and NF-
kB pathways during the pathogenesis.    
The authors analyzed diverse DLBCLs in which they identified a group of missense 
mutations affecting the stability and the function of PRDM1 other than cases of epigenetic 
silencing when BCL6 was co-expressed. 
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Furthermore, in two mouse models of PRDM1 conditional KO (in B cells or restricted to 
GC cells) there was an increased incidence of lymphoproliferative disease and of DLBCL 
with constitutively active NF-kB pathway, resembling the human ABC-DLBCL 
phenotype170. 
In another work, using a more sophisticated mouse model that combines NF-kB activation 
with PRDM1 inactivation, Calado and co-workers showed that the two altered pathways 
cooperate in the development of lymphoma171. This last observation is even more 
interesting from a therapeutic point of view: in fact the standard treatment CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisone) is ineffective for half of the 
patients that develop DLBCL (and in particular ABC-DLBCL). It has been demonstrated 
that some chemotherapy resistant B cell lymphoma cell lines express a shorter isoform of 
PRDM1, also known as PRDM1β. The treatment of resistant cell lines with rituximab and 
doxorubicin decreases both PRDM1β level and the phosphorylated form of NF-kB. In 
addition the treatment with NF-kB signal inhibitors down regulate PRDM1β and affect cell 
growth. These observations suggested that NF-kB in this tumors regulates PRDM1β levels 
and open new perspectives in the diagnosis and the treatment of these tumors172. 
As mentioned above, some of the PRDM genes generate more than one isoform: the full-
length product and an alternative product that lacks the PR domain but is otherwise 
identical for the rest of the protein. Interestingly, the different products behave in a so-
called “yin-yang” fashion where the full-length proteins participate in tumor suppression 
and cell cycle arrest, while a high relative expression of the isoform missing the PR 
domain is linked to oncogenesis173.  
The shorter product of PRDM1 (referred as PRDM1β, while the full length is PRDM1α) 
was identified as a transcript highly expressed in human myeloma cell lines, starting from 
a single novel exon upstream of the exon 4 of PRDM1 gene and in frame with the rest of 
the protein. Consequently the relative protein retains the DNA binding ability but 
completely lacks the amino terminal 101 aminoacids containing the PR domain (Fig.7) 160.  
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In a luciferase reporter assay PRDM1β showed weak repressive ability towards the 
heterologous promoter even if it was functionally able to recruit HDACs. Recently it has 
been demonstrated that the loss of PRDM1β promoter methylation is frequent in B 
lymphoma cell lines and in primary DLBCL174 and might account for the unbalanced 
PRDM1α/PRDM1β ratio in tumors compared with normal plasmacell.  
Immunocytochemical staining for PRDM1 and tissue microarray analysis reported 
PRDM1 expression also in other B cells neoplsms – like lymphoplasmacytic lymphoma, 
plasmablastic lymphoma and oral mucosa lymphoma – as well as in T-cell lymphomas. 
Moreover this study showed a subset non-ABC DLBCL co-expressing PRDM1 and BCL6 
(independently from IRF4 expression) and correlated with worst prognosis175. Despite in 
this last article the authors presented a consistent collection of healthy and pathological 
samples they did not consider a differential expression between PRDM1α and PRDM1β 
and in general PRDM1 protein functionality176. 
In T-cell malignancies, like for DLBCL, it has been found a relationship between 
PRDM1β expression and chemotherapy resistance. The treatment of PRDM1β expressing 
resistant cells with the proteosome inhibitor bortezomid blocks NF-kB transcription and 
contemporary decreases PRDM1β, IRF4 and c-myc expression that regulate T-cell 
transformations. Also in this case PRDM1β expression could be related to NF-kB pathway 
and it might suggest new ways of treatment175.  
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5. Glioblatoma multiforme 
Our initial data indicated that PRDM1 is expressed not only in early neural progenitors of 
adult brain but also in the most common adult brain tumor, the glioblastoma multiforme 
(GBM). The observed evidence turned our attention on a previously unidentified role of 
PRDM1 in normal brain homeostasis and in its aberrant counterpart. Consequently we 
consider worthwhile to mention some important aspects of high-grade gliomas.  
Figure 7. PRDM1 human gene. (Top) The gene encompasses 23,6 kb DNA in humans, from 106534195 to 
106557814 (hg19-Feb, 2009) in the long arm of chromosome 6. It encodes 7 exons. The open reading frame spans all 
7 exons. The mRNAs encoded by PRDM1 have two transcript isoforms, PRDM1alpha and PRDM1beta, which are 
5164 and 4675 bp long, respectively. The shorter isoform is generated by usage of the alternative promoter located in 
intron 3 and contains a different 5' untranslated region. It lacks the 5' in frame portion of the coding region present in 
PRDM1alpha. 
(Bottom) PRDM1α is the larger isoform and contains 825 amino acids. It has a PR domain at the N-terminal portion 
(86-207 aa) of the protein, which is related to the SET domain found in many histone methyltransferases. In contrast 
to bona fide SET-domain proteins, the PR domain in PRDM1 does not possess intrinsic histone methyltransferase 
activity. Five C2H2-type zinc fingers which represent the DNA binding domain, are present at the C-terminal portion 
of the protein (575-707 aa). The middle part of PRDM1 (about 300-400 aa) is rich in proline and serine. PRDM1β 
lacks the N-terminal 101 amino acids of the PRDM1alpha, and has a truncated PR domain. PRDM1β has been shown 
to be functionally impaired in its transcriptional repression activity (Gyory et al., 2003). The proximal 3 zinc fingers 
in PRDM1/Blimp-1 delta exon 6 variant are disrupted (Schmidt et al., 2008).  
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The high-grade glial tumor GBM is the most common and aggressive – with a median 
survival of 14 months after diagnosis - brain tumor in adulthood. Morphologically it 
represents a heterogeneous collection of distinct diseases comprising astrocytic, 
oligodendroglial and mixed neoplasms177 whereas histologically GBM is designated as a 
grade IV high grade glioma (with necrosis and microvascular proliferation) according to 
the world health organization (WHO) classification178. The majority of GBMs are primary 
lesions, while a minority of them can arise from a previous lower-grade tumor and they are 
called secondary GBMs179,180. 
Glioblastoma multiforme (GBM) comprises also a fraction of cells with similar 
characteristics of neural stem cells. Increasing evidence supports the hypothesis that GBMs 
arise from the transformation of neural stem cells residing in the SVZ.  
Infact, high-grade gliomas can be generated when the appropriate genetic lesion are 
directed in either neural progenitor or glial cell types181-183. There is a large consensus, 
however, on neural stem and progenitor cells representing a likely candidate for the origin 
of human gliomas184, in spite of difficulties in retrospectively determining if human 
gliomas originated from a differentiated cell (astrocytes or oligodendrocytes) that acquired 
trans-differentiation abilities (necessary to generate and maintain glioma cell-type 
heterogeneity) or if common glial progenitors had overcome anti-proliferative restrictions. 
However the cell of origin of human gliomas is under debate and the generation of mouse 
models recapitulating human pathogenesis will help in clarifying this issue. 
In the last few years the improvement of high-throughput sequencing technologies 
contributed to the identification of the critical pathways involved in the pathogenesis of 
GBMs (Fig. 6). The major effort has been done by The Cancer Genome Atlas (TCGA) 
which create a collection of data that helped in classifying different tumors - 
histopathologically indistinguishable – on the basis of their molecular profile185-188 
(http://tcga-data.nci.nih.gov/). Moreover new bioinformatic tools have been developed in 
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order to integrate genomic, expression and epigenetic data and identify different classes of 
GBMs on the basis of overlapping features188,189.  
The pathogenesis of GBM involves the inactivation of tumor suppressive pathways (p53 
and Rb) and the oncogenic activation of receptor kinase pathways, which result in 
uncontrolled cell proliferation, invasion and angiogenesis (Fig. 8). The activation of 
signalling pathways might be achieved at different levels: a) through the overexpression of 
cell growing stimuli (PDGF, bFGF, FGF2, EGF, TGFα and IGF1) and of their receptors 
(EGFR, ERBB2, PDGFRA, MET), b) trough the deletion of negative regulators of the 
signalling pathways (PTEN, NF1) and c) by mutations that results in constitutively active 
receptors (such as EGFRvIII). 
According with the TCGA classification, four GBM classes have been recognized to 
possess distinct molecular subtypes: proneural, classical, mesenchymal and neural 183,190. 
Proneural GBMs are characterized by a transcriptional profile similar to that of neural 
development and they are frequently occurring in younger patients. The genes more 
frequently activated in proneural subtype comprise factors important for oligodendrocytic 
(PDGFRA, OLIG2, TCF3, NKX2-2) and neural (SOX, DCX, DLL3, ASCL1 and TCF4) 
differentiation. Recently also the mutation of isocitrate dehydrogenase 1 (IDH1) and to a 
lesser extent of IDH2 has been identified in some proneural tumors as well as in other 
lower grade gliomas and secondary GBMs. The gene is mutated, only in one single copy, 
in the active site for substrate recognition, determining an aminoacid sobstitution (R132H) 
that is responsible for a gain of function event. In fact, the mutated copy acquired a higher 
affinity for α-ketoglutarate which is converted, with a NADPH dependent reduction, into 
R(-)-2-hydroxyglutarate (2-HG). This metabolite alters many functions of the cell such as 
hypoxic sensing, demethylation and fatty acid metabolism, which determine a 
characteristic cell expression profiling. The identification of IDH1 related mutation had 
important implications for diagnosis since it was seen to correlate with better prognosis. 
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Therefore it represents a good example of how clinics and molecular medicine have to be 
integrated in order to stratify patients that will receive more focused treatments191. 
Highly proliferative cells and major chromosomal losses or amplifications are the principal 
characteristics of classical GBMs. In particular gain of chromosome 7, and losses of 
chromosomes 10 and 9p21.3 determine EGFR amplification and the deletion of PTEN and 
CDKN2A respectively. Transcriptionally these tumors resemble neural precursors and 
stem cells expression such as activated Notch and Sonic hedgehog signalling pathways. 
Classical GBMs derived the name for the property they have to respond to classical 
radiotherapy since p53 pathway is not perturbed. 
Mesenchymal subtype shows frequently mutated NF1, p53 and CDKN2A. Furthermore 
two recent studies went more into the details of the mesenchymal transcriptional 
program188,189. In the first study188 combining computational analysis and targeted 
functional assay the authors identified two transcription factors (C/EBPβ and STAT3) as 
the master regulators of the genetic regulatory networks that initiate and maintain the 
malignant and aggressive state of the mesenchymal subtype.  Togheter with these two 
major players other four transcription factors – RUNX1, FOSL, bHLH-B2 and ZNF-238 – 
control the entire signature. In the second study189 the HIPPO pathway transducer TAZ 
was seen to co-segregate with mesenchymal GBMs while to be epigenetically silenced in 
other lower-grade gliomas. In addition TAZ was seen to augmente the grade and the 
penetrance of a mouse model of high-grade glioma.  
Finally neural subtype strictly separates form the others but none alteration is particularly 
enriched and it is characterized by the expression of neuronal markers (NEFL, GABRA1, 
SYT1 and SLC12A5). 
This complex characterization might also contribute to the improvement of current 
therapies since standard treatment protocols have remained relatively unchanged and 
involve aggressive radio- and chemo-therapeutic treatment following surgery192. Also 
prognosis might take advantage of this database by identifying single molecules that 
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follow the histology. At the moment the prognostic markers are confined to IDH mutation 
that we mentioned before181, the methylation status of the DNA repair enzyme O6-
methylguanine-DNA methyltransferase (MGMT) that is predictive of sensitivity to 
alkylating chemotherapy193,194 and of progression incidence195, and finally the 1p/19q co-
deletion in oligodendroglioma196. 
Additional studies will clarify glioblastoma biology integrating genomic studies, animal 
models of disease and careful study of the human tissue. 
 
 
 
Figure 8. Aberrantly signaling pathways in GBM. Figure adapted from Nature 2008 Oct 23;455(7216):1061-8. 
The Cancer Genome Atlas (TCGA) Network has recently released an integrated  analysis of genomic and 
transcriptomic data in order to delineate the molecular profile of human Glioblastoma multiforme (GBM). These 
studies revealed a number of recurrent mutations that involve different signaling networks.  Herein the primary 
sequence alterations and amplifications of a) RTK/Ras/PI(3)K, b) p53 and c) signaling pathways are shown. Red 
indicates activating genetic alterations, with frequently altered genes showing deeper shades of red. Conversely, blue 
indicates inactivating alterations, with darker shades corresponding to a higher percentage of alteration. For each 
altered component of a particular pathway, the nature of the alteration and the percentage of tumours affected are 
indicated. Boxes contain the final percentages of glioblastomas with alterations in at least one known component 
gene of the designated pathway.   
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Chapter 2 - MATERIALS AND METHODS 
2.1 Isolation and culture of mouse sub-ventricular stem cells 
The brain form mouse was removed and placed in PBS with penicillin and streptomycin 
(0.1 mg/ml). The tissue corresponding to the periventricular region (SVZ) was dissected 
and incubated in Earl’s balanced salt solution (EBSS) containing papain (1 mg/ml), EDTA 
(0.2 mg/ml) and cystein (0.2 mg/ml) at 37°C for 1 hour. The disgregated tissue was 
collected by centrifugation at 200 g for 10 minutes and resuspended in 1 ml of NEC 
medium and plated in uncoated flask at a concentration of 8x103 cells/cm2. NEC medium 
contains: Neurocult NS-A Basal medium (Stem Cell Technology), 10% proliferation 
supplement (Stem Cell Technology), 2 µg/ml heparin, (Sigma) 10 ng/ml hFGF 
(PrepoTech), 20 ng/ml hEGF (Prepotech). When neurospheres reached approximately 300-
500 microns in diameter were passaged harvesting them by centrifugation (200 g per 10 
minutes) and triturating in 200 µl of medium with automatic pipette. 
2.2 Cell culture 
Ntera2-D1 were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% FBS, 2mM glutamine and 1% penicillin/streptomycin, passed every 2-3 days 
with 0.005% trypsin-EDTA for the efficient expansion of the cell line. To induce 
differentiation cultures were treated with 10 µM of all-trans-retinoic acid (ATRA R2625, 
Sigma-Aldrich company), supplemented every 48 hours.  
Murine E14Tg2a embryonic stem cells (ESCs) were grown without feeders in standars ES 
medium supplemented with b-mercaptoethanol 14.3 mM (GIBCO), LIF 1000 U/mL 
(Chemicon) and 2i [1uM MEK – PD0325901 (Cayman chemicals) and 3uM GSK3 – 
CHIR99021 (Axon biochemicals)]. The cells were incubated at 37°C in a humidified 5% 
CO2 incubator. 
Pelicci G. group kindly provided cancer stem cells lysates derived from human 
glioblastoma tumors. The samples were collected accordingly with the Ethical Committee 
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for human experimentation of IEO (European Institute of Oncology) and all patients 
signed and approved consent document prior to surgery. 
2.3 Quantitative real time (RT) PCR 
Total RNA was prepared from 1x106 cells using RNAeasy Kit (Qiagen) following 
manufacturer’s instructions. Total RNA was used for first strand cDNA synthesis using 
random primers and M-MuLV reverse transcripase (Finnzymes) according with 
manufacturers’ instructions. 
Each SYBR green reaction was performed in 20 µl containing 10 µl of 2x SYBR green 
master mix (Applied Biosystem), 1 µl of 0.5 µM primer mix and 8 ng of cDNA. Oligos 
were designed at the boundary of exon‐intron to avoid amplification of genomic DNA. 
The PCR reaction was run on HT9700 PCR machine with the following cycling 
parameters: 1 cycle at 50°C for 2 min, 1 cycle at 95°C for 10 min followed by 40 cycles 
where the temperature ramp from 95°C to 60°C in 1min. Each sample was run in 
duplicate. The mean value of the replicates for each sample was calculated and expressed 
as cycle treshold (CT:  cycle number at which each PCR reaction reaches a threshold, set 
within the linear range of all reactions). For each sample, the CT value of the endogenous 
control (GAPDH) was subtracted to the CT value of the target gene (ΔCt) to obtain 
comparable values. Then, the relative amount of gene expression is calculated as the 
difference (ΔΔCt) between the ΔCt of the test sample and of the control sample. Finally, 
the relative expression is expressed as 2‐ΔΔCt. 
2.4 RNA-sequencing 
After quality control, mRNA was processed following the standard Solexa protocol 
recommended for mRNA sequencing. Paired-end 50bp-reads were aligned to the mm9 
reference genome and to the Mus Musculus transcriptome (Ensembl build 63, Flicek et al. 
2012) using TopHat  1.3.1 (Trapnell et al. 2009). We allowed up to two mismatches and 
specified a mean distance between pairs (-r) of 120 bp. 
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Transcripts abundances were quantified using Cufflinks 1.2.1 (Trapnell et al. 2010). 
Differentially expressed genes were called using Cuffdiff 1.2.1 (Trapnell et al. 2010). For 
the next steps of the analyses we considered the quantifications at the level of single genes. 
Genes showing an FPKM (fragments per kilobase of exon per million fragments mapped) 
equal or higher than one in at least one sample were retained. Differentially expressed 
genes were defined using an FDR <= 0.05 and no threshold on the fold change. For 
transcript quantification we used options –N (upper-quartile normalization) and -u. 
Tracks for the UCSC genome browser (Fujita et al. 2011) were generated considering only 
the uniquely alignable fraction of the total reads. Tracks were linearly re-scaled to the same 
sequencing depth. 
2.5 Chromatin Immunoprecipitation (ChIP) – sequencing and ChIP-qPCR 
For ChIP cells were fixed on the bulk with 1% formaldehyde in PBS. Cross-linking was 
allowed to continue for 10 minutes at 37°C and stopped by addition of glycine (0.125 M as 
final concentration) followed by an additional incubation of 5 minutes. Fixed cells were 
washed twice with PBS and then lysed in SDS Buffer (50 mM Tris pH 8.1, 0.5% SDS, 100 
mM NaCl, 5mM EDTA and protease inhibitors). Cells were pelleted by centrifugation and 
resuspended in 5 ml of IP Buffer (100 mM Tris pH 8.6, 0.3% SDS, 1.7% Triton X-100, 5 
mM EDTA). Cells were disrupted by 12-15 pulses (30 seconds each) of sonication with a 
tapered J-microtip (6.5 mm) in a Branson digital sonifier 250D, at a power setting of 50%, 
yelding genomic DNA fragments with a bulk size of 200-500 bp. For each 
immunoprecipitation, 1 ml of diluted lysate (15x106 cells/ml) was precleared by addition 
of 50 µl of blocked protein A beads (50% slurry protein A- Sepharose from Amersham; 0.5 
mg/ml fatty acid free BSA, Sigma). Samples were immunoprecipitated at 4°C with 
magnetic dynabeads protein G and A (Invitrogen) mix 1:4 previously saturated with two 
different antibodies specific for PRDM1 (anti-PRDM1 polyclonal rabbit serum got from 
Surani lab and BLIMP-1/PRDI-BF1 (C14A4) rabbit mAb #9115) or with normal rabbit 
IgG (Santa Cruz Biotechnology sc-2027). Beads were washed and crosslink was reversed 
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with Elution Buffer (1% of SDS, NaHCO3 0.1M and proteinase K) overnight at 65°C and 
the DNA was directly used for quantitative PCR or quantified with picogreen for 
sequencing. We tried to improve ChIP experiment performing a repeated cycle of 
immunoprecipitations. Basically following the over-night immunoprecipitation with the 
first antibody we collected the unbound fraction and we used it for a second-round IP with 
the other antibody (two different sequential IP were done exchanging antibodies order). In 
this way we increased the probability to sequester PRDM1-chromatin complexes reaching 
different protein epitopes that may be masked by fixing the cells and finally obtaining a 
reasonable DNA amount for sequencing purposes. 
Raw 36bp-reads were aligned to the hg18 genome using Bowtie 0.12.7 (Langmead et al 
2009). All the reads with a unique match to the genome with two or fewer mismatches (-m 
1 –v 2) were retained. Peak calling was performed against input DNA using MACS v1.4 
(Zhang et al 2008) with default parameters. Peak lists were annotated over RefSeq genes 
lists using GIN (Cesaroni et al 2008, priority set to “gene” and promoter definition to “-
20000”). 
For ChIP of the histone marks, we used standard procedure using anti- H3K4me3 (Ative 
Motif 31210), H3K27me3 (Millipore 07-449), H3K9me3 (ChIP grade ab8898) and 
H3K9me2 (ChIP grade mAbcam 1220) antibodies. Real-time PCR was performed with 6 
µL of DNA per reaction and 200 nM primers, diluted in a final volume of 20 µL in SYBR 
Green Reaction Mix (Perkin Elmer, Boston, MA). Accumulation of fluorescent products 
was monitored by real-time PCR using a GeneAmp 9700 Sequence Detector (ABI). Each 
PCR reaction generated only the expected specific amplicon, as shown by the melting-
temperature profiles of final products (dissociation curve, automatically measured by the 
Taqman 9700). 
2.6 Immunoblot 
To prepare total cell extracts tissue-cultured cells were harvested by centrifugation, washed 
in PBS and directly lysed in Laemly 5x buffer followed by sonication for 30 seconds in a 
	   48	  
Tekman CV26 sonicator set at 25% amplitude. The lysates were clarified and loaded in 8% 
SDS-polyacrylamide gel. The immunoblot was performed with Immobilon-P (Millipore) 
transfer membrane previously equilibrated in methanol. Rabbit monoclonal antibody anti-
PRDM1 (Cell Signaling) was diluted 1:500 in 5% milk PBS-tween 0.1% and used for 
protein detection. 
2.7 Immunofluorescence 
Cells were fixed in 4% paraformaldehyde, washed in PBS and incubated in blocking buffer 
(PBS, 2% BSA, 0.1% Triton). Primary antibody was incubated at 4°C overnight. Primary 
rabbit polyclonal anti-PRDM1 antibody (Abcam ab59369) and secondary anti-rabbit 
FITC-conjugated antibody were diluted 1:25 and 1:50 respectively in blocking solution. 
Images were acquired with an Olympus fluorescence microscope with the ScanR 
automated image acquisition software. Image analysis was performed with the ImageJ 
software.  
2.8 BrdU proliferation assay 
For proliferation assay cells (3x106) at different time points were pulsed for 10 minutes in 
medium containing 33 µM BrdU. Harvested cells were pelleted and resuspended in 750 µl 
of PBS and fixed by adding 2250 µl of pure ethanol for 30 minutes in ice. Fixed cells were 
resuspended in 1 ml of 2N HCl and incubated at room temperature for 25 minutes and after 
3ml of 0.1 M Sodium Borate addition (Na2B4O7) incubated for other 2 minutes at RT. 
The cells were stained with anti-BrdU antibody diluted 1:5 in PBS, 1% BSA and with 
secondary anti-mouse Cy5 conjugated antibody. 
2.9 Animal experiments 
PRDM1-mVenus mice were imported from Saitou M. Lboratory. PRDM1-NestinCre and 
PRDM1-ErCre were generated by crossing PRDM1flox/flox mice with Nestin-Cre mice or 
Cre-ERT2 (The Jackson Laboratory). P53HE-ErCre and PRDM1-P53HE-ErCre mice were 
generated by crossing TP53 heterozygous mice  (The Jackson Laboratory) with Cre-ERT2 
or PRDM1-ErCre. The latter two mice were subjected to intracranial orthotopic 
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inoculation of concentrated lentivirus resuspended in PBS (106 copies/ml) expressing 
mutated Ras (HRasV12). In anesthetized mice (by intraperitoneal injections of Avertin 
0.1mg/10g body weight) 2 µl of virus were stereotaxically injected into the nucleus 
caudatus (coordinates: 0.7 mm posterior, 3 mm left lateral, 3.5 mm in depth from the dura) 
of 8-weeks-old mice. A cohort of mice were administered by oral gavage with 5mg of 
tamoxifen dissolved in 80 µl of corn oil for two treatments of 5 days each separated by one 
week of no treatment. The mice were maintained until development of neurologic signs 
and then killed for the analysis of tumor histology and immunohistochemestry. 
The mice were housed in plastic cages and were kept in a regulated enviroment (22°C; 
55% humidity) with a 12 hours light/dark cycle (lights on at 7:00 AM). Food and water ad 
libitum. 
2.10 Tissue histology 
For histology, mouse brains were formalin fixed and paraffin-embedded. 5 µm sections 
were cut and placed onto polysine slides (Thermo Scientific). For Hematoxylin and Eosin 
staining sections were deparaffinized in xylene, rehydrated in a graded alchol series and 
stained in Mayer hematoxylin. After counterstain in eosin-phloxine B solution the 
sectiones were dehydrated in alchol and cleared in xylene. 
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Chapter 3 - RESULTS 
3.1 PRDM1 expression correlates with multipotency in neural stem and progenitor 
cells (NSPCs) 
In order to functionally and mechanistically characterize PRDM1 as a developmental 
regulator, we first needed to identify an appropriate experimental framework where to 
perform genome wide studies. Following initial screenings in different model systems we 
decided to assay for previously unanticipated role of PRDM1 in the mammalian central 
nervous system (CNS).   
Available in situ hybridization data suggest that PRDM1 is highly expressed in neural 
territories during mouse development: in particular it is expressed in the key precursor 
structures (the leading anterior mesendoderm and the prechordal plate) from which the 
forebrain originates42,51 (Fig. 9A, source http://genome.ucsc.edu/cgi-
bin/hgVisiGene?hgp_listSpec=prdm1&hgp_doSearch=search). However in neuronal 
derived tissues PRDM1 expression is confined to the primitive retinal neurons (Fig. 7B) in 
the outer neuroblastic layer from about embryonic day (ED) 11 until birth and PRDM1 
null embryos are not affected in the development of the head structures42. 
In the adult brain PRDM1 expression is undetectable (Fig. 9C) and it is slightly higher in 
the olfactory bulbs (Fig. 9D-F http://brainstars.org/probeset/1420425). Nonetheless, since 
PRDM1 protein is often restricted to a small cell population in a particular developmental 
stage, in situ hybridization (ISH) and gene expression profiles might not be sensitive 
enough to appreciate PRDM1 expression differences.  
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As previously described, in zebrafish PRDM1 is expressed in neural progenitors and in 
mammals it is critical for homeostasis of many tissues. These observations prompted us to 
better investigate if PRDM1 might be involved also in adult mouse neurogenesis.  
To test this, we took advantage of PRDM1mVenus mice47, a transgenic reporter strain that 
expresses membrane-targeted Venus (mVenus) under the control of PRDM1 regulatory 
elements (Fig. 10). Following mVenus tracer is possible to recapitulate directly in vivo the 
dynamic expression pattern of PRDM1. From the brain of C57BL/6 wild type (WT) and 
PRDM1mVenus adult mice we isolated the cells residing in the subventricular zone (SVZ) 
of the cerebral cortex (the adult neural stem cell niche), a compartment enriched for neural 
stem and progenitor cells (NSPCs). In a few days, from the cell suspension neurospheres 
started to form and we expanded them in culture in order to enrich for NSPCs (schematic 
representation in Fig. 11).  
A B C 
D E 
F 
Figure 9. PRDM1 expression in mouse neural tissues. A) In situ hybridization (ISH) of PRDM1 in mouse embryo. 
PRDM1 is induced early in the anterior definitive endoderm, mesoderm of head process and prechordal plate. 
Source: Mahoney Lab: MGI Reference: Mouse Brain Organization Revealed Through Direct Genome-Scale TF 
Expression Analysis. B) Immunohistochemistry (IHC) of PRDM1 in ectoderm-derived tissues. Sagittal section 
through the eyes of ED11 embryo. PRDM1 is expressed in the outer neuroblastic layer of neural retina. Source: MGI 
Reference: The dynamic expression pattern of B lymphocyte induced maturation protein-1 (Blimp-1) during mouse 
embryonic development. C) PRDM1 is not detectable in mouse brain after birth using IHC. Source: Allen Brain 
Atlas (ABA). D) and E) expression energy cross section images of PRDM1 in the olfactory bulb anterior and 
posterior respectively. Source: Allen Mouse Brain Atlas, Allen Instiute for Brain Science. F) Mouse PRDM1 relative 
gene expression in adult brain compartments. Source: BrainStars classification of 48 brain regions by multi-state 
gene analysis. 
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After some passages (around 10) the dissociated neurospheres were subjected to flow 
cytometry. We realized that the population of NSPCs was morphologically heterogeneous 
both in WT as well as in PRDM1mVenus derived cells and it could be separated in two 
subpopulations, called P1 and P2 (Fig. 12A and B). Both of them were gated and analysed 
for fluorescence emission. Interestingly a significant enrichment of Venus positive events 
was detected in both the subpopulations but more significantly in the one with higher side 
scatter (SSC), the P1 (equal to the 22.9% Fig 12E and F), while considering the total 
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Figure 10. Scheme of the Prdm1mVenus transgene. The genomic loci and exon–intron structures of the Prdm1. 
The position at which sequences of the fluorescent reporters are recombined are also shown. Source: Ohinata Y et al. 
Reproduction 2008;136:503-514 
    
  
Figure 11. Derivation and expansion of mouse neural stem and progenitor cells (NSPCs) from adult brain. A) 
Picture adapted from Charles D. Stiles and David H. Rowitch, Neuron 58, June 26, 2008. Scheme of frontal section 
of the adult mouse brain showing the subventricular zone (SVZ) (red and enlarged on the right) adjacent to the lateral 
ventricle. SVZ progenitors include type B (blue), C (amber), A (green) cells and ciliated ependymal cells (pink) that 
line the lateral ventricle. Type B cells divide very slowly and express the markers indicated. They give rise to 
transient amplifying type C cells that in turn generate type A neuroblasts that contribute to the rostral migratory 
stream in most cases. B) Stem and progenitor cells derived from the sub-ventricular zone (SVZ) of adult WT and 
PRDM1mVenus reporter mice were propagated in culture as neurospheres. At each passage the spheres were 
disaggregated and seeded as single cells to expand the pool of NSPCs to be analyzed by FACS. 
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NSPCs (P1 and P2 together) the percentage of Venus positive cells was 4% if compared 
with the total WT NSPCs (Fig. 14D and 14B respectively). Neurospheres are composed of 
different population of cells, which are believed to have various levels of differentiation 
potential. The most primitive NSC, among other markers, can be discriminated using 
FACS analyses by means of physical properties such as size and granular complexity, 
forward (FSC) and side scatter (SSC), respectively (Fig. 12-14). The total Venus-positive 
(Fig. 13B) and Venus-negative cells (Fig. 13A) of PRDM1mVenus sample were 
independently plotted in order to see differences in the morphology of the cells and we 
noticed that putative PRDM1 expressing cells were augmented in SSChigh while PRDM1 
negative clustered in FSC/SSClow. Furthermore, a stringent gate was set on WT 
neurosphere cells in order to identify the lowest fraction of cells with the NSC properties 
characterized by high FSC/SSC (Fig. 14A and 14C). This population resulted to be highly 
similar between WT and transgenic animals neurospheres. Interestingly, when Venus-
positive neurosphere cells were separately analyzed we found fourfold-enrichment in the 
FSC/SSChigh population (Fig. 14E), indicating that Venus expressing population is 
enriched for NSC. We also observed an eight-fold enrichment of SSChigh cells that is a 
morphological feature of adult NSCs. 
Although promising, these first evidence were indirect proves of PRDM1 expression in 
neurogenic areas that we directly corroborated by testing PRDM1 presence in different 
brain compartments. Firstly, we confirmed that PRDM1 protein was indeed expressed in 
NSPCs while it was not detectable in primary cortical astrocytes (Fig. 15), moreover 
PRDM1 expression level counter-correlated with GFAP level (astrocytic marker) in a 
NSPCs in vitro differentiation assay (Fig. 16). Afterwards, we examined the PRDM1 
transcript in brain lysates. While in the majority of the tissues analyzed PRDM1 was not 
revealed (or it was expressed at very low level), in line with the ATLAS database, I found 
relatively higher PRDM1 expression in the olfactory bulb (OB) and in rostra migratory 
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stream (RMS) (Fig. 17), two neurogenic areas that contain migrating neural progenitors 
which differentiate to become functionally effective.  
Collectively the data indicated that by means of lineage tracing protein and gene 
expression experiments we demonstrated that PRDM1 is expressed in the brain of the adult 
mice and that it correlates more with properties of uncommitted neural progenitors.  
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   Figure 12. Initial characterization of PRDM1 expression in adult mouse brain. 
 A and B) FACS analysis of freshly dissociated NSPCs. Stem and progenitor cells derived from the 
subventricular zone (SVZ) of adult WT (A) and PRDM1mVenus (B) reporter mice were propagated in 
culture as neurospheres and then FACS analysed as single cells (see scheme in Fig. 9). C and D). The 
cells separate in two morphologically different sub-populations (P1 and P2 in the top panels) and both of 
them are enriched for Venus positive cells (blue curve) if compared with the non-fluorescent WT cells 
(red curve). E and F) The Venus positive cells correspond to the 22.9% of the P2 population in 
PRDM1mVenus (F) compared to the negative WT control (E). Laser exitation at 488 nm and emission 
detected in FL2-H channel (at 542 nm). 
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Figure 13. Venus-negative and Venus-positive NSPCs are morphologically different. (A) Cells from 
PRDM1Venus mice. Distribution of the TOTAL Venus negative population. (B) Distribution of the TOTAL Venus 
positive population. 
  
Figure 14. NSPCs morphological analysis. A stringent gate was set on NSPC cells (A and C) in order to identify 
the lowest fraction of cells with the NSC properties of high FSC/SSH. This population resulted to be highly similar 
between WT (0.275 in A) and transgenic animals neurospheres (0.2 in C). Interestingly, when Venus positive 
neurosphere cells (F) – resulting from the subtraction of PRDM1mVenus positive events (D) from the negative 
control (B) - were separately analyzed we found a four fold enrichment in the FSC/SSC high population (0.872 in E) 
and eight fold enrichments in SSC high population (1.08 in C and 8.01 in E) indicating that Venus positive cells may 
be enriched for NSC.  
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Figure 15. PRDM1 protein is expressed in NSPCs and not 
in differentiated astrocytes. Primary NSPCs and astrocyte 
cultures were derived from 7 days old mice using established 
methods (McCarthy and de Vellis, 1980). BMI1 is normally 
expressed in stem and progenitor cells and is used as positive 
control. Actin is used as loading control. 
  
Figure 16. PRDM1 expression is down regulated during in vitro differentiating primary NSPCs. Untreated 
NSPCs (NT) or treated with 10 ng/mL of BMP4 for 3 and 6 hours. GFAP is used as positive control of cellular 
differentiation. TBP is used as reference gene for normalization. PRDM1 difference in gene expression between the 
treatments has been assessed by one-way ANOVA and it is statistically significant (p=0.0163). 
  
Figure 17. Relative PRDM1 expression in different mouse brain tissues. OB, olfactory bulb; HIPPO, 
hippocampus; RMS, rostra migratory stream; SVZ sub-ventricular zone; CC, corpus callosum; CERVELL, 
cerebellum; STRIATO; CORTEX S, temporal cortex; CORTEX I, frontal cortex. TBP is used as reference gene for 
normalization.  
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3.2 PRDM1 loss has consequences on NSPCs global gene expression 
These data prompted us to better investigate PRDM1 biological function in a previously 
unexplored context that is the central nervous system (CNS). In order to do this we 
generated conditional knock out (CKO) mice where PRDM1 expression was abrogated in 
NSPCs in vivo. This mouse model was obtained by crossing mice that possess loxP sites in 
introns flanking exons 6 to 8 of the Prdm1 gene (http://jaxmice.jax.org/strain/008100.html) 
with mice that express Cre recombinase under the control of the rat nestin promoter and 
enhancer (http://jaxmice.jax.org/strain/003771.html). The efficiency of PRDM1 deletion 
was assessed both at genomic level in WT, conditional heterozygous (CHE) and CKO 
NSPCs (Fig. 18) and at expression level in WT and CKO NSPCs and whole brain (Fig. 
19). Mice that were homozygous for PRDM1 deletion in the brain were viable, normal in 
size and did not display any gross physical or behavioural abnormalities.  
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Figure 18. PRDM1 conditional knock out (CKO) mouse model. A) Schematic representation of  PRDM1FLOX 
locus. This mouse model possesses loxP sites in introns flanking exons 6 to 8 of the PRDM1 gene. When these 
mutant mice are bred to mice that express Cre recombinase, resulting offspring will have exons 6 to 8 deleted in the 
cre-expressing tissue. Two couples of primers were designed to assess the deletion of PRDM1 gene. The primers 
called “FLOXED” amplify only WT allele, while “DELETED” primers are able to amplify only in case of 
recombination (deletion) event. B) Genomic DNA derived from NSPCs of PRDM1flox crossed with Nestin Cre mice 
and amplified with the two different PCR designed assays. The values are normalized with 18S gene. 
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In order to obtain a more global view on the effect of PRDM1 loss of function in adult 
neurogenesis we carried out RNA sequencing in WT and PRDM1 CKO NSPCs. NSPCs 
were isolated from the subventricular zone of adult mice brain by enzymatic digestion. 
Dissected regions were mechanically dissociated to obtain single cell suspension that was 
plated in the selective culture medium (for details see Material and Methods 2.1). By using 
this methodology, NSPCs formed spherical clusters called neuropsheres, which were 
mechanically dissociated to a single-cell suspension and replated to expand the pool. After 
few passages (around 5) we extracted total RNA from WT and PRDM1 CKO neurospheres 
(Fig. 20). Starting with total RNA, the messenger RNA was first purified using polyA 
selection (Illumina), then chemically fragmented and converted into single cell cDNA 
using random hexamer priming. Next, the second strand was generated to create double-
stranded cDNA that was ready for library construction for paired-end sequencing.  
Transcripts abundance and differentially expressed genes were called and analysed using 
the parameters described in Material and Methods 2.4 demonstrating that the loss of 
PRDM1 function influenced NSPCs genome wide gene expression profile.  The 
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Figure 19. PRDM1 is efficiently deleted in the Nestin expressing cells and in their neural derivatives. PRDM1 
qRT-PCR performed with NSPCs (A) or whole brain lysate (B). TBP is used as reference gene for normalization. 	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overlapping list of co-regulated genes obtained from two independent experiments in the 
absence of PRDM1 (76 genes were downregulated and 117 upregulated) was significantly 
enriched for metabolic pathways (glycolysis/gluconeogenesis, fructose and mannose 
metabolism), amino-acids metabolism (pentose phosphate pathway), nervous system 
development and function (Wnt/β-catenin signalling), membrane trafficking (clathrin 
mediated endocytosis) and HIF1α signalling pathway (not indicated in the table but it was 
the sixth pathway more represented) (Fig. 21). Combining our dataset with a published 
transcriptome database for astrocytes, neurons and oligodendrocytes197 we observed that 
deregulated genes in PRDM1 null NSPCs are variably expressed in all the differentiated 
brain cell types (Fig. 22).  
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Figure 20. RNA sequencing of WT and PRDM1 CKO NSPCs. The transcriptome of WT (black track) and 
PRDM1 KO (blue track) neurospheres was obtained from two independent experiments (two WT mice and two CKO 
mice). A) Genome browser snapshot of replicate 1. B) Genome browser snapshot of replicate 2. In both the replicates 
is clear the deletion of the region comprising exons 6 to 8 of PRDM1 locus in KO tracks. 
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Furthermore, in the same database the authors identified cell-type enriched signalling 
pathways and interestingly Wnt/β-catenin signalling and glycolysis/gluoconeogenesis were 
more significantly associated with astrocytes and as mentioned above also over-
represented in our list of KO deregulated genes.    
In the validation step we observed a fair correlation between RNA-sequencing profile and 
independent qRT-PCR experiments with approximately 50% of randomly selected genes 
being defined as deregulated by both platforms (Fig. 23). We believed that these results are 
on line with the expected degree of variation due to heterogeneity in neurosphere cultures. 
Notably, however we fully recapitulated by gene expression profiles the more 
differentiated phenotype of PRDM1 depleted NSPCs as being the glial fibrillary acidic 
protein (GFAP) - a well-known marker of astrocytes and glial cells – up regulated in KO 
cultured cells  (Fig 24A and 24B). Accordingly with a pro-differentiation effect of PRDM1 
deletion, we noticed that KO NSPCs proliferated less than WT (Fig. 25). In fact in 
neurosphere-assay KO cells were slower in self-renewing ability and formed smaller 
spheres (Fig. 25A and 25B). Indeed, at high density cell suspension (150 cells per 
microliter) 2.9% of WT neurospheres were bigger than 100 µm (in diameter), on the other 
hand only 0.4% of the KO neurospheres reached the same size (see Table 2 for details).   
Figure 21. Summary of Ingenuity Systems 
Pathway Analysis (IPA) of PRDM1 KO 
regulated genes. The analysis showed that 
the regulated genes in PRDM1 KO NSPCs 
compared to WT belong more significantly to 
the listed pathways. Threshold was set up at 5 
but HIF1α signaling was the sixth more 
enriched pathway.  
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To verify this phenotypic observation we plated low-density (1 cell per microliter) single 
cell suspension of NSPCs in a 96 well and we waited for new sphere formation. Indeed we 
saw that KO NSPCs were drastically impaired in the ability to re-form new colonies (Fig. 
25C) and in some cases the newly form neurospheres had a differentiated morphology 
(Fig. 25D and 25E).  
Together the data presented here suggested that the loss of PRDM1 impaired NSPCs in-
vitro self-renew and it influenced the transcriptional profile of genes that are important in 
all mouse brain terminally differentiated cells. 
 
 
DIAMETER (µm) WT spheres (%) KO spheres (%) 
 10 - 20 19.3% 17.3% 
20.1 -  50 44% 47.3% 
50.1 - 100 34% 35% 
> 100 2.9% 0.4% 
 
Table2. Neurospheres counting in WT and KO NSPCs culture. 
 
Figure 22. PRDM1 dependent 
genes are expressed in all mouse 
brain terminally differentiated 
cells. Regulated genes after 
PRDM1 ablation in NSPCs are 
indicated on the left of the heatmap 
(down regulated in green and up 
regulated in red). The heatmap 
represents the expression level of 
each individual gene in the three 
major classes of brain terminally 
differentiated cells. Source: The 
Journal of Neuroscience, 2 January 
2008, 28(1): 264-278; doi: 10.1523/
JNEUROSCI.4178-07.2008. The 
expression level was normalized 
and plotted on a logaritmic color 
scale, with blue representing low 
expression and red representing 
high expression. 
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Figure 23. Validation by qRT-PCR of RNA-seq. Expression level of selected genes up regulated (in red) or down 
regulated (in green) in KO NSPCs was checked in an independent experiment for RNA-seq validation. The graph 
shows that part of the up regulated genes were confirmed (above the blue line settled at 1.5 fold increase) while down 
regulated did not recapitulate RNA- seq profile.  
  
Figure 24. GFAP gene is significantly up regulated in 
PRDM1 KO NSPCs. A) RNA-seq profile shows GFAP 
expression pattern in WT NSPCs (black) – almost 
undetectable - and in KO NSPCs (blue) where it is well 
expressed. B) qRT-PCR validation of GFAP expression 
in an independent experiment. TBP is used as reference 
gene for normalization. 
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3.3 Identification of PRDM1 regulatory network 
To gain insight into the molecular mechanism by which PRDM1 regulates 
developmentally important processes, we overcame the paucity of neurospheres, by 
moving to an established model system of neural differentiation where we could set-up and 
perform ChIP-sequencing: the Ntera2-D1 (NT2-D1) embryonic carcinoma cell line.  NT2-
D1 is widely adopted differentiation model system that shares many properties with human 
embryonic stem cells (expression of pluripotency markers such as Oct4, Nanog, and Sox2; 
in vivo differentiation towards different lineages –e.g. teratoma formation; in vitro 
commitment towards defined developmental routes –e.g. neural commitment) and that can 
differentiate in vitro into neurons upon exposure to all trans retinoic acid (ATRA). We 
successfully differentiated NT2-D1 in vitro as revealed by gene-expression, morphology 
and proliferation changes during ATRA exposure (Fig. 26 and 28).  
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Figure 25. Loss of PRDM1 impairs NSPCs in vitro self renewal. A and B) Phase contrast images of neurospheres 
WT (A) and PRDM1 KO (B) NSPCs. PRDM1 KO spheres appears generally smaller in size and fewer in number. C) 
The neurospheres of each sample were disaggregated and plated as single cell in a 96 well plate. The graph represents 
the average number of new spheres in each well of a 96 well plate. Bars show mean values of spheres/well and 
corresponding standard error of two independent experiments. KO cells are impaired in the formation of new spheres 
when plated at low density single cell suspension. D and E) Phase contrast images. The newly formed neurospheres 
are also morphologically different. KO NSPCs (E) in these conditions show a differentiated morphology compared 
with WT (D).  
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Next, we tested for the expression of PRDM1 during NT2 differentiation by using TaqMan 
tool (Fig. 27) and qRT-PCR (Fig. 28 C): we collected the cells at different time points (not 
treated, 1, 3, 5, 7 and 14 days exposed to ATRA) to measure expression along with cellular 
proliferation changes trough 5-bromo-2-deoxyuridine (BrdU) incorporation until day 7. 
Interestingly, we noticed that the peak of PRDM1 expression coincided with the time point 
at which the cells start to exit the cell cycle and to commit to a more differentiated state, 
acquiring morphological changes. In particular, PRDM1 expression pattern correlated with 
the early stages of cellular differentiation as it was up regulated around the third day of 
ATRA induction and down regulated immediately after (as detected by transcript and 
protein level) (Fig. 28C and 28A-B respectively). Consistent with this, BrdU cell 
incorporation progressively decreased after the third day of ATRA treatment and the cells 
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Figure 26. Ntera2-D1 (NT2-D1) cells in-vitro differentiation. (Top) Light microscopy images of NT2 cells not 
treated and after retinoic acid (ATRA) treatment. (Bottom) ATRA induced NT2-D1 differentiation determine the loss 
of pluripotency markers as Oct4 and Nanog (graphs on the left) and the acquirement of neural-specific markers as 
Pax6 and Nestin (graphs on the right). Gene expression changes were detected by real-time quantitative PCR (qRT-
PCR) and they are represented as relative intensity by using gapdh housekeeping gene for mRNA level 
normalization. 
  
	   65	  
started to accumulate in G1 phase from this time point onwards, until they practically exit 
the cell cycle after one week of treatment (Figure 28 C bottom).  
The human PRDM1 gene contains an alternative promoter capable of generating a PR 
domain deleted protein (called PRDM1-β), which lacks 101 amino acids comprising most 
of the PR domain. We designed a quantitative real-time PCR (qRT-PCR) assay to 
discriminate the expression pattern of each of the two isoforms that differentiate for length 
and for the presence of a unique exon in PRDM1β. In early time points of ATRA 
induction, PRDM1β was hardly detectable and it started to be expressed at day 7 when the 
full-length isoform (PRDM1α) was not more detectable (Figure 29).  
We further investigate the role of PRDM1 in NT2-D1 differentiation, an interesting model 
system amenable to mechanistic analyses. We performed Chromatin-immunoprecipitation 
sequencing (ChIP-seq) experiment for PRDM1 at the third day of ATRA treatment (at the 
time point in which only PRDM1α is expressed) by two sequential rounds of IP (scheme of 
the experiment in Fig. 30 B) using two different anti-PRDM1 antibodies. One of these 
antibodies was kindly provided by Surani A. laboratory and it was already validated for 
ChIP experiments. We checked the specificity of the other antibody (commercially 
available) by performing ChIP-western blot (ChIP-WB) (Fig. 30A).  
From ChIP-sequencing we obtained 10 millions uniquely aligned reads forming 4700 
peaks (IP versus input) calculated with a threshold p-value of 1e-5 on a non-redundant list 
of genes. The genomic distribution of the peaks shows a clear enrichment for promoters 
(27%). However, since PRDM1 is also present in substantial amounts at intergenic binding 
sites (Fig. 30C), it could be additionally involved in long distance mechanisms of gene 
regulation. The sequences surrounding the peaks (Fig. 30D) were then analysed by MEME 
to search for enriched de novo DNA-binding motif(s) (Fig. 30E). MEME outcome 
confirmed at a genomic scale the main PRDM1 consensus motif (IRF-like), and reinforced 
the confidence in the validity of our approach and of the target genes identified.  
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Figure 27. PRDMs expression during ATRA induced NT2-D1 differentiation. In the y, relative mRNA 
expression level; in the x, days of RA treatment. Data are represented as a heatmap according to the color-code scale 
shown on the right. Each line corresponds to a TaqMan probe for each PRDM members.  
  
Figure 28. PRDM1 expression pattern during NT2-D1 differentiation. PRDM1 is a nuclear DNA binding protein 
whose expression is induced upon ATRA treatment. PRDM1 expression peaks at the third day of ATRA treatment as 
the same time point when the cells start to exit the cell cycle. (A) Immunofluorescence of PRDM1 in NT2-D1 cells 
exposed to ATRA (detected by anti-PRDM1 polyclonal antibody from Abcam). (B) Immunoblot of endogenous 
PRDM1 (detected by anti-PRDM1 polyclonal antibody from Cell signaling) in NT2-D1 whole lysate, before and 
after 3 days of ATRA treatment. (C) (Top) PRDM1 expression level during NT2-D1 differentiation detected by qRT-
PCR normalized to gapdh values. In the y, relative mRNA expression level; in the x, days of RA treatment. (Bottom) 
Percentage of proliferating cells during ATRA differentiation. In the y, percentage of BrdU positive cells; in the x, 
days of ATRA treatment. 
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Figure 29. PRDM1α and PRDM1β 
are counter-regulated during NT2 
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Figure 30. PRDM1 Chromatin immunoprecipitation sequencing (ChIP-seq) in NT2-D1. (A) ChIP of 
endogenous PRDM1 in NT2-D1 cells at the third day of ATRA treatment using two different antibodies. One got 
from Surani group, already used for ChIP purposes and the other commercial (Ab2) and validated in chip-conditions 
(by ChIP western blot) before the usage for ChIP-qPCR. Using both antibodies we obtained enough DNA to 
sequence. (B) Flowchart of the ChIP experiment. The IP were performed in duplicate (IP1 and IP2) by precipitating 
chromatin in two IP rounds. C) Genomic distribution of PRDM1 peaks. D) Distribution of the peaks around RefSeq 
transcription start site (TSS). E) Logo derived from MEME of the de-novo binding motif.  
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We randomly selected 30 putative target regions from the ChIP-seq (with different binding 
affinity according to the p-value assigned) for single binding region ChIP quantitative PCR 
(ChIP-qPCR) validation (Fig 31). The specificity of PRDM1 direct target binding sites was 
compared with the chromatin immunoprecipitated with rabbit IgG (mock) as negative 
control (Fig. 31A). Furthermore the ChIP was performed also in the cells untreated (in 
which PRDM1 is expressed as a basal level) showing, as expected, low PRDM1-binding 
affinity (Fig. 31B). We were able to confirm the binding for 27 regions measured as the 
enrichment on the total chromatin before the IP (input) and comparing with mock 
experiment (some of the validated regions are graphed in Figure 31A-B). We confirmed 
that the quality of the assigned peaks is high (90% validation), and therefore we proceeded 
to an in-depth bioinformatic analyses. To find any relation among PRDM1 target genes we 
searched the Database for Annotation, Visualization, and Integrated Discovery (DAVID) 
for enriched gene ontology (GO) terms (Fig. 32). We found the top ranking gene clusters 
in nucleus and in negative regulation of transcription - as expected being a known 
transcription regulator – but most importantly new classes of genes emerged to be part of 
PRDM1 regulatory network such as the regulation of RNA metabolic processes (splicing) 
and factors important for neural differentiation and embryonic morphogenesis  (Figure 32). 
The latter observation is quite remarkable as no role was so far ascribed for PRDM1 in 
neural development. Moreover the Table 1 shows the lists of PRDM1 direct targets that 
were also up regulated or down regulated in NSPCs after PRDM1 KO and they represent 
interesting candidates to understand PRDM1 pathway in neurogenesis.  
We concluded that NT2-D1 cell line is a useful tool where to study, at molecular level, 
some features of neural lineage commitment. As further proof, PRDMs – recently reported 
to be important for mammalian neurogenesis – were dynamically regulated during NT2-D1 
differentiation evaluated at different time points (represented in the heatmap Fig 27).   
These data strongly supported the already established role of PRDM1 as a master regulator 
important for developmental processes and extended it to neural differentiation.  
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Collectively our results represented the first profile of PRDM1 binding on a genomic scale 
and pave the way for the discovery of novel biological functions since to date no other 
comprehensive studies in human or mouse identified the PRDM1 global regulatory 
network using unbiased methods. 
 
 
0	  
0.02	  
0.04	  
0.06	  
0.08	  
0.1	  
0.12	  
0.14	  
N
2	  
LZ
TS
1	  
RA
BI
IF
IP
4	  
TC
F1
5	  
PR
DM
16
	  
TA
L1
	  
FA
M
5B
	  
BD
N
F	  
M
AR
K2
	  
EI
F2
AK
1	  
PO
U
3F
1	  
TR
AT
1	  
PT
GF
RN
	  
N
ES
	  
FA
N
CC
	  
IP1	   IP2	   MOCK	  	   0.24 A 
%
 b
ou
nd
/in
pu
t 
0	  
0.01	  
0.02	  
0.03	  
0.04	  
0.05	  
0.06	  
0.07	  
0.08	  
N
2	  
SR
EB
F1
	  
TR
IM
44
	  
PO
U
3F
1	  
PC
N
A	  
PL
O
D1
	  
PT
M
A	  
EI
F2
AK
1	  
AR
GL
U
1	  
SY
DE
2	  
TR
AT
1	  
AG
AP
1	  
PR
DX
6	  
IP	  NT	   IP	  RA	  B 
%
 b
ou
nd
/in
pu
t 
Figure 31. ChIP-qPCR validation of PRDM1 ChIP-seq. (A) Target regions of newly identified PRDM1 binding 
sites were validated by ChIP-qPCR in two indipendent experiments (IP1 and IP2). (B) Comparison between the ChIP 
performed in the cells treated with ATRA or non-treated (NT). N2 is a negative region used as control and mock 
experiment is ChIP performed using rabbit control IgG. In the y, the enrichments are calculated as the percentage on 
the input chromatin; in the x, the regions selected for primers design. 
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Figure 32. Enriched gene ontology (GO) in PRDM1 target genes obtained from Database for Annotation, 
Visualization, and Integrated Discovery (DAVID). The top ranking gene clusters in transcriptional regulator 
activity. Transcription factors involved in neurogenesis (in red) and embryonic development (in green) were also 
present in this list and the genes of these classes are indicated.  	  	  
Table 1. PRDM1 direct target genes are deregulated in NSPCs after PRDM1 KO. List of the genes 
that are directly bound by PRDM1 (ChIP-seq profile) and regulated after PRDM1 KO in NSPCs (RNA-
seq profile). 
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3.4 Analysis of PRDM1 molecular mechanism 
Our data suggested that PRDM1 preferentially represses genes that are essential for 
determining cell fate decisions during embryonic development as previously shown for 
Polycomb (PcG) proteins198,199 via mechanisms that are not yet fully elucidated. 
Interestingly we observed a significant overlap between PRDM1 target promoters 
identified in human embryonic carcinoma cell line (NT2-D1) and the regulatory network 
controlled by PcG in human embryonic stem cells (hESC)200. We strengthened this 
observation by measuring also a substantial overlap between PRDM1 target promoters and 
H3K27me3 (a reversible repressive modification mediated by PcG) targets in hESC (69 
out of 322)201 (Figure 33A). Consequently we though that the common PRDM1/PcG 
promoters were more likely to be stably repressed during cellular differentiation. This 
hypothesis was supported by available datasets in IMR90 cells (a fibroblast cell line in 
which PRDM1 is expressed) whereby PRDM1 and PcG common genomic targets were 
enriched for H3K9 methylation (a more heritable repressive marker than H3K27me3)201 
meaning that these genes were stably silenced in the differentiated cells. From our dataset 
we selected three candidates for the validation of the hypothesis that were also PcG targets 
and positive for H3K27me3 in undifferentiated NT2 dataset202. We designed a “primer 
walking” (Fig 33 B) centred in the target promoters and we used it to amplify the DNA 
coming from ChIP performed at different time points during NT2-D1 commitment  
(untreated NT, 3, 7 and 21 days of ATRA treatment). As you can appreciate from Fig. 34 
we observed that in the selected regions H3K9me3 increased during NT2-D1 
differentiation. However we did not establish a direct role for PRDM1 in driving PcG 
complexes to the target promoters neither we correlated this evidence with a diminished 
expression of the selected genes since in NT2-D1 they were barely expressed and since in 
this undifferentiated cell line the global levels of both of H3K9 repressive marks were 
considerably higher than in hESC.  
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Figure 33. PRDM1 target genes are developmentally important and overlap with H3K27me3 in hESC. A) 
PRDM1 binding sites at the promoters overlap with bivalent domains in human embryonic stem cells (Venn 
diagram), source: Cell. 2010 October 15; 143(2): 313–324   B) PRDM1 ChIP-seq peaks in NT2-D1 after ATRA 
(black track) and H3K27me3 in NT2-D1 untreated cells (red tracks), source: O'Geen H, Squazzo SL, Iyengar S, 
Blahnik K, Rinn JL, et al. (2007) Genome-Wide Analysis of KAP1 Binding Suggests Autoregulation of KRAB-
ZNFs. PLoS Genet 3(6): e89. doi:10.1371/journal.pgen.0030089. Three promoters (BDNF, KALRN and WNT3) 
were selected to check epigenetic changes during NT2 differentiation. Dashed line and letters (a, b, c, d) indicate the 
genomic regions where we designed the primers to amplify the DNA obtained from histone marks ChIP (see next 
picture). 
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We proposed therefore to further extend these observations by looking at other cell model 
systems where PRDM1 plays analogous functions (e.g. germ cells) in order to broaden this 
mechanistical insight to a validated model system of PRDM1 function.  
These preliminary data supported the hypothesis that PRDM1 target genes are marked by 
overlapping repressive histone modifications in differentiating cells and it might explain 
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Figure 34. PRDM1 target genes are marked by overlapping repressive histone marks in differentiating NT2-
D1. The regions a, b, c, d, e indicate the genomic regions amplified along the target promoters after ChIP (see Fig. 
31). Each region was amplified in NT untreated NT2 and 3, 7 and 21 days after ATRA. Each histogram bar 
corresponds to a single time point (ordered from NT to 21) in the indicated region. In the y, the enrichments are 
calculated as the percentage on the input chromatin; in the x, the regions selected for primers design (from a to e, see 
Fig. 31). 
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the mechanism by which the reversible transcriptional regulation mediated by PcG in 
ESCs is converted in permanent modifications of developmentally important genes during 
cellular differentiation.  
3.5 PRDM1 reinforcement of PcG epigenetic repression in a model of in vitro germ 
cell differentiation 
To investigate whether the proposed mechanism may hold true in a model system where 
PRDM1 function is biologically relevant we set up a model of in vitro cellular 
differentiation towards the germ cell lineage by the ectopic expression of deleted in 
azoospermia-like (Dazl) gene (Fig. 35A), which is an established germ cell developmental 
regulator. We selected Dazl stably expressing mouse ESC (mESC) clones (Fig. 35B) and 
we tested them for PRDM1 induction (Fig. 35C). PRDM1 expressing clones were allowed 
to differentiate by removing ESC medium components (2i medium and LIF) and 
supplementing it with serum. Progressively the cells stopped proliferating and down 
regulated pluripotency markers (Fig 35D).  
Also in this case, for the validation of the mechanism, we selected as candidates 
developmentally important genes marked in mouse ESC with bivalent domains and that 
were both PcG (in mESCs) and PRDM1 (in NT2-D1) target genes (Fig 36A). Among this 
list of genes we choose GATA4, PAX6 and TAL1 because they were representative 
factors for development, being implicated in the formation of all the three germ layers: 
endoderm, ectoderm and mesoderm respectively. We looked at the expression level of 
these genes in differentiated mESCs verifying that PAX6 and TAL1 were efficiently down 
regulated when compared with WT mESCs, whereas GATA4 (in Appendix I) showed a 
strong up regulation (Fig. 36B).  
We performed ChIP for post-translational histone modifications and we verified the quality 
using gapdh, RUNX1 and PU.1 promoters as controls of ChIP quality. 
Epigenetic modifications at the promoters of these candidate genes reflected their 
transcriptional regulation: notably both PAX6 and TAL1 acquired H3K9me2 during 
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cellular differentiation while GATA4 (in Appendix I) showed undetectable levels of 
repressive histone mark (Fig 34D). We observed a general enrichment for H3K4me3 in 
mESC expressing DAZL that might correlate with swapping of cell culture medium from 
2i to serum containing medium.  
Concluding our mechanistic studies in a germ cell model system corroborated the 
observations made in NT2-D1 cells. We demonstrated in a biologically significant model 
system that two developmental important PRDM1 target genes were acquiring definitive 
repressive marks during cellular differentiation, an important clue since terminally 
differentiated cells showed different layers of epigenetic repression but the mechanisms 
responsible for that are still unclear. 
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Figure 36. PRDM1 reinforces PcG epigenetic repression during germ cell commitment. A) PRDM1 target 
promoters in NT2-D1 overlap with bivalent domains and with PcG targets in hESCs. Three of these genes were 
choose for mechanism validation. B) PAX6 and TAL1 expression was efficiently repressed during germ cell 
differentiation, while GATA4 was up regulated (see Appendix I). C) Internal controls of H3K4me3 (gapdh) and of 
H3K27me3 and H3K9me2 (PU.1, RUNX1 and NEG) ChIP efficiency. D) Epigenetic profile of PAX6 and TAL1 
promoters in WT and differentiated (DAZL) cells. In the y, the enrichments are calculated as the percentage on the 
input chromatin; in the x, the regions selected for primers design. GATA4 values are in Appendix I. 
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3.6 The role of PRDM1 in GBM 
Since we achieved evidences for PRDM1 expression in neural progenitors and because 
PRDM1 is a tumor suppressor in the tissues where it exerts functional activity, we 
wondered whether it might also be involved in the most common malignant brain tumor of 
the adulthood that is the glioblastoma multiforme (GBM). In order to investigate this 
possibility we took advantage of the datasets generated by the large effort of the CANCER 
GENOME ATLAS (TCGA)182,203, which described a gene expression-based molecular 
classification of GBM subtypes. Extrapolating PRDM1 values from this dataset we were 
able to appreciate that its expression is significantly higher in the GMB subtype named 
mesenchymal (Fig. 37C). We experimentally supported this observation by testing 
PRDM1 expression in different samples of GBM. Both PRDM1 isoforms (α and β) were 
highly expressed in GBM mesenchymal cell line (GBM166) as compared to normal foetal 
human NPCs (Fig. 37A). PRDM1 was also up regulated in murine GBM initiating cells 
(Ink4a/Arf -/-; EGFRVIIIhigh NPCs) originated from transformed NSPCs while it was not 
detected in similarly engineered astrocytes (Fig. 37B). Finally we observed that PRDM1 
expression was restricted to a limited number of human GBM derived stem cells, possibly 
in line with its expression being subtype-dependent. As control, BMI1 - which is a well-
known stem cell regulator - was expressed in nearly all of the lines.  
Consequently we wanted to directly correlate the effect of PRDM1 deletion during the 
development of GBM. We exploited this issue by using mouse genetics for the creation of 
GBM in a WT or conditionally mutant PRDM1 background. In our mouse model of GBM 
we combined heterozygous germ line mutation of p53 with brain orthotropic inoculation of 
constitutively active RAS form (HRasV12). These mice were also transgenic for tamoxifen 
inducible Cre ricombinase that was administered by oral gavage in order to obtain PRDM1 
conditional deletion (Fig. 38A). We successfully obtained Cre-mediated recombination in 
the brain of the treated animals (Fig. 38B) meaning that tamoxifen efficiently overcame 
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blood brain barrier. Some of the treated animals were sacrificed before tumor development 
(around two months after H-RasV12 inoculation) since they were suffering for unrelated 
causes (more probably for consequences of tamoxifen toxicity and evident dermatitis).  
We are currently collecting the first results of this experiment that are presented in the 
AppendixII. 
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Figure 37. PRDM1 expression in GBM. A) PRDM1 alpha and beta are highly expressed in human mesenchymal 
GBM cell line (GBM166 – Pollard-Smith-Dirks Cell Stem Cell) while their expression is faint in human foetal neural 
progenitor cells CB660 (Pollard-Smith-Dirks Cell Stem Cell). B) PRDM1 is strongly up regulated in murine glioma 
initiating cells derived from transformed NSPc while tumorigenic astrocytes did not express PRDM1. C) PRDM1 
expression is significantly higher in a specific subtype of GBM named “Mesenchymal”. Source: TCGA D) PRDM1 
expression in cancer stem cells derived from different human GBMs. 
  
Figure 38. Generation of a spontaneous mouse model of GBM. A) PRDM1FLOX or WT/P53heterozygous/ER-
Cre mice were infected by orthotropic inoculation with lentivirus carrying mutated oncogenic HRasV12 (see text). 
These mice were orally administered with tamoxifen to activate Cre ricombinase in order to delete PRDM1FLOX 
locus. B) PRDM1 was efficiently deleted in the forebrain of PRDM1-FLOX/P53 heterozygous/ER-CRE comparing 
with PRDM1 WT mice. 
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Chapter 4 – DISCUSSION 
In our quest for the characterization of the mechanisms by which PRDM1 regulates direct 
target genes during cell fate commitment, we obtained several molecular and biological 
hints that shed light on previously unreported PRDM1 function. Below we discuss our 
findings and the implications for future research.  
4.1 PRDM1 is expressed in neural progenitor cells: implications in adult 
neurogenesis.  
Here we presented evidence of PRDM1 expression and function in adult neural progenitor 
cells of the mouse brain reinforcing the already established role of PRDM1 as a cell fate 
determinant and extending it to an unexplored tissue: the mammalian brain. 
Piece of data in low model organisms for development (zebrafish and Xenopus) pointed 
out the relevance of PRDM1 in the specification of both peripheral and central nervous 
system structures. However, in mammals PRDM1 – despite being expressed in the 
embryonic tissues deputed to anterior patterning – seemed to be dispensable for forebrain 
and head formation. This observation does not contrast with an important role of PRDM1 
in adult stem cells; in fact, other transcriptional regulators such as Bmi1 are also 
dispensable for embryonic development, yet required for the maintenance of adult neural 
stem cells. Concerning this, we noted that mice, in which PRDM1 was conditionally 
deleted in Nestin positive neural progenitor cells, were apparently not compromised in the 
development. Nonetheless, future studies will be required to elucidate this matter, since we 
did not perform in deep histopathological analyses to formally exclude its role in 
embryonic neurogenesis.  
Through genetic tracing experiments we clearly demonstrated that PRDM1 is expressed in 
neural stem and progenitor cells (NSPCs). NSPCs derived from the subventricular zone 
(SVZ) are a heterogeneous mix of different cell types with variable levels of pluripotency 
(the ability of self renew and to differentiate in any cell type) and with distinct physical 
properties. Phenotypical analysis of NSPCs from WT and PRDM1mVenus knock-in mice 
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was assessed to some extent by using forward scatter (FSC) and side scatter (SSC) 
parameters (representing cell-size and cellular granularity respectively). Our results 
highlighted that PRDM1mVenus negative cells were confined in the FSC/SSCmid-low a 
morphological feature associated with minor ability in neurospheres formation and lower 
multipotency. Conversely, when compared with the bulk of NSPCs and with negative 
control (WT NSPCs), Venus-positive cells were found four-fold enriched in the 
FSC/SSChigh population typical of more immature neural stem cells and eight fold enriched 
in FSClowSSChigh a morphologically different population of neural stem cells that increases 
at later stages of development204.  
Importantly, genetic depletion of PRDM1 in NSPCs further demonstrated that the absence 
of PRDM1 correlates with a more differentiated phenotype, which was assessed by the 
ability to form neurospheres in vitro and by gene expression profile experiments (RNA-
sequencing and qRT-PCR).  
Specifically we used neurosphere formation assay – a culture system in which neural stem 
and more immature progenitor cells selectively proliferate to form multicellular 
aggregates, the so called neurospheres – by plating the cells at a very low density and 
waiting for the formation of secondary derived clones. PRDM1 KO neural stem cells were 
not properly maintained since they were forming fewer and smaller neurospheres 
comparing with WT cells. At the second re-plating, in the same growing conditions, KO 
cells displayed also a different morphology more similar to neural differentiated cells. 
Anyway keeping the cells in standard plating conditions (at a density of 150 cells per 
microliter) we easily expanded in culture both WT as well KO NSPCs and we propagated 
them to investigate genome wide expression changes caused by PRDM1 deletion.  
Confirming previous observations, in genome wide expression analyses, we showed that 
five up regulated genes in PRDM1 KO NSPCs are among the top score cell type specific 
markers used to defined astrocytes: Aqp4, Gfap, Atp1a2, Ntsr2 and ApoE, while we did 
not identify any neuronal specific marker and only Mbp for oligodendrocytes. While this is 
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not surprising, taking into account the prevalence of astrocytic commitment of NSPCs in 
vitro, nonetheless the genes that are deregulated in PRDM1 KO NSPCs were variably 
represented in the three major brain cell types – astrocytes, neurons and oligodendrocytes – 
meaning that PRDM1 dependent genes are expressed in terminally differentiated brain 
cells. While a major set of the PRDM1-dependent genes as revealed by our RNA-
sequencing analysis showed a good concordance with RT-qPCR validation in independent 
samples, the incomplete validation of our profiles urge reticence when drawing single-gene 
conclusions without prior validation. Future studies should aim at identifying more 
precisely genes that depend on PRDM1 for their appropriate expression in vivo, possibly 
combining several independent replica. Notably, however, we fully recapitulated by gene 
expression profiles, the more differentiated phenotype of PRDM1-depleted NPCs as being 
the glial fibrillary acidic protein (Gfap) - a well-known marker of astrocytes and glial cells 
– the gene more up regulated in CKO cultured cells. Other genes preferentially expressed 
in astrocytes followed the same trend of Gfap in qRT-PCR (Vegfα, Ndrg2, Acss2, Cav1, 
Ntsr2) but also a couple of neuronal specific genes were substantially up regulated (Pfkp 
and Bsg). Moreover we consistently correlated reporter signal localization, genetic tracing 
and functional ablation experiments, with actual PRDM1 expression in primary cells. In 
fact, PRDM1 protein was detected in NSPCs derived from adult mice, while it was 
undetectable in cortical astrocytes. Accordingly, PRDM1 was also down regulated in 
NSPCs induced to differentiate with BMP4.  
Together, our experimental procedures are indicative of a positive role for PRDM1 in 
neural stem cell self-renewal. Due to the technical challenges to be overcome when blindly 
analyzing neural stem cells proliferation defects in vivo, the nature and the extent of 
PRDM1 deletion defects on the adult neurogenesis await future studies, possibly driven by 
a prior genetic lineage tracing in vivo for PRDM1 expressing cells progeny, which would 
significantly ease the identification of specific compartments where PRDM1 defects can be 
reasonably scored. 
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Furthermore, also the precise mechanism by which PRDM1 may sustain NSPCs self-
renewal has not been demonstrated and will require ad hoc experiments. In fact, 
neurosphere formation could be maintained in higher plating cell density (at a density of 
150 cells per microliter). With these conditions we easily expanded in culture both WT as 
well as KO NSPCs and we easily propagated them. 
Two additional observations were interesting in our gene expression analysis. First, the 
search for statistically enriched canonical pathways performed with IPA tool (Ingenuity 
System) resulted in a strong representation of terms involved in 
Glycolisis/Gluconeogenesis, a metabolic pathway characteristic of astrocytes to promote 
synaptic activity197. Second, while PRDM1 consensus sequence (IRFs-like, which contains 
GAAAG) was not statistically overrepresented, one of the top score matrixes identified 
was the Hypoxia Inducible Factor 1 alpha (HIF1α). Accordingly Hif1α signaling was the 
sixth more enriched canonical pathway in PRDM1 dependent genes. Hif1α mediates 
cellular responses to hypoxia. It is expressed throughout the whole body but in normoxia 
conditions it is degraded in most cell types and tissues. Interestingly in adult brain 
neurogenic tissues and in NSPCs this activator it is continuously expressed and stabilized 
and it is important for the correct neural differentiation205. Based on our results we can 
hypothesize that PRDM1 and HIF1α might be co-expressed in NSPCs and counteract for 
the regulation of common gene targets but with opposite effects being PRDM1 mainly 
known as a transcriptional repressor and HIF1α as a transcriptional activator. This 
represents a common mechanism of PRDM1 target genes regulation already described in 
plasmacell, where PRDM1 and BCL6 counteract for effector versus memory cell 
phenotype, or in dendritic cells, where PRDM1 represses whereas IRF8/PU.1 activates 
CIITA gene. While we will refer for the confirmation of this hypothesis to further 
experiments it is tempting to speculate that PRDM1 and HIF1α may have opposite 
outcomes on common targets in NSPCs, and it is intriguing to observe that in PRDM1 KO 
NSPCs, Vefgα – a HIF1α known target gene – was significantly up regulated. 
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4.2 PRDM1 regulatory network analysis: implications for target genes regulation 
during cell fate commitment.  
PRDM1 plays critical role in development and structurally it is characterized by an amino 
terminal PR/SET domain and five C2H2 zinc fingers at the carboxyl terminal that mediate 
DNA binding, nuclear localization and recruitment of histone modification enzymes163,206. 
These properties account for its ability to regulate cell fate decisions and tissue 
homeostasis by sequence specific DNA binding. Nonetheless still a gap exists between the 
functional relevance of PRDM1 in many contexts and the complete knowledge of its 
regulatory network.  In specific model systems and through indirect gene expression 
profile, a set of putative PRDM1 target genes has been reported for germ cells54. To date, 
only few direct target genes have been identified in mammals, possibly due to technical 
limitations in obtaining high-quality genome wide profiles for this transcription factor.  
Indeed, we had to face with diverse technical solutions before being successful in PRDM1 
chromatin immunoprecipitation (ChIP). We screened several commercially available and 
group-restricted antisera in order to identify the one with highest specificity under ChIP 
conditions. Furthermore, we need to refine our ChIP protocol to account for the low 
sensitivity of the immunoprecipitation process.  
To our knowledge, here we report the first genome wide profile for PRDM1 in mammalian 
cells.  
During plasmacell differentiation, PRDM1 modulates INF-gamma response after viral 
infection by directly repressing MHC CIITA gene. In this context it was demonstrated, in a 
luciferase reporter assay, that PRDM1 bind IRF-E sequences and compete with IRF-1/IRF-
2 activators for CIITA promoter binding207. In our experimental settings (NT2-D1 cells) 
we found that in differentiating cells PRDM1 binding site is strikingly similar to IRF-E, 
extending the competitive model of PRDM1 and IRF interaction beyond the INF-gamma 
mediated induction and extending the number of in vivo PRDM1 direct binding sites. 
Additional motif discovery and co-expression analysis in NT2-D1, revealed the possible 
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interaction also between PRDM1 with SP1 and AP2 transcription factors. Notably these 
proteins also act as general transcriptional activators, reinforcing the concept that PRDM1 
may oppose to unwanted transcriptional activation of cell type specific targets. 
Together our data represented a solid ground to comprehensively achieve PRDM1 
functional network during cellular differentiation. They integrated two genome wide 
studies (RNAseq and ChIPseq) that extended the current knowledge about the spectrum of 
PRDM1 biological roles and also contributed to the identification of new PRDM1 binding 
regions, important for cell fate commitment.  
Lineage-commitment is associated with the progressive and specific restriction of genome 
accessibility208. This process has been correlated with the acquisition of repressive histone 
post-translational modifications. For instance, differentiated embryonic stem cells (ESCs) 
present large scale regions of H3K9me2, a modification catalyzed by and dependent on the 
histone lysine methyltransferase G9a209. Polycomb group proteins (PcG) regulate the 
repression of developmentally important genes in order to ensure correct cell fate decisions 
in part through the deposition of H3K27me3198,199. Interestingly, in more differentiated 
foetal lung fibroblasts, H3K27me3 mark is overlaid by an additional repressive histone 
post-translational modification, the H3K9me3201. Furthermore, PcG target genes in 
terminally differentiated astrocytes are permanently silenced through DNA methylation210. 
All these reports suggest that PcG mediated repression, which is considered transient and 
reversible, is reinforced by additional layers of chromatin associated post-translational 
modifications. 
Nonetheless the precise mechanisms by which this may occur have not yet been 
discovered. PRDM1 directly associate with G9a38 and here we showed that it binds to PcG 
target genes in ESCs and that these acquire H3K9me2 and H3K9me3 in differentiated 
fibroblasts that express PRDM1. It is tempting to speculate that PRDM1 is one of those 
cell fate transcription factors, which are involved in establishing a definitive transcriptional 
repressive landscape in terminally differentiated cells. 
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Our data have been generated in NT2-D1 cells, which are embryonic carcinoma cells (the 
malignant counterpart of ESCs), capable of differentiating into mature neurons upon to 
exposure to retinoic acid. While the relation of NT2-D1 with normal cell types is 
questionable, this model has been successfully used to dissect the mechanistical repression 
of PcG target genes during neural lineage commitment211, which acquires confidence into 
our mechanistical description of BDNF, KALRN and WNT3A repression.  
In the attempt of increasing the biological relevance of our findings to a model system 
where PRDM1 is biological required, we (partly) differentiated mouse ESCs into germ 
cells, through the over-expression of DAZL, and we used them to evaluate the epigenetic 
status of developmentally important genes (PcG and PRDM1 common targets). We 
demonstrated that the expression of TAL1 and PAX6 genes was down regulated after 
PRDM1 induction and that their promoters acquired higher levels H3K9me2 than control 
ESCs. Further functional experiments such as RNAi, and genetic rescue, will be required 
to precisely demonstrate the involvement of PRDM1 in this novel mechanistical detail of 
transcriptional repression.  
4.3 PRDM1 expression and possible involvement in Glioblastoma multiforme. 
Since PRDM genes are often tumor suppressors in the tissues where they exert their 
activity166 and since adult brain cancers possibly arise from transformed neural stem 
cells212, we searched for evidences of PRDM1 in human GBM, the most common form of 
brain cancer in adults. 
Interestingly, not only PRDM1 is highly expressed in GBM182, but also it significantly 
correlated with a particular GBM subtype called mesenchymal. In support of this 
observation we detected high levels of PRDM1 (both human PRDM1 isoforms α and β) 
expression in a human mesenchymal GBM cell line (GBM166213). Furthermore, PRDM1 
is expressed in murine GBM initiating cells (Ink4a/Arf-/-; EGFRVIII NPCs), which 
prompted us to investigate the functional role of PRDM1 in a spontaneous mouse model of 
GBM.  
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While experimental, our model system is related to human pathology. The conditional 
deletion of PRDM1 was obtained by crossing mice carrying floxed PRDM1 alleles with 
transgenic mice that express Cre recombinase under the control of a tamoxifen inducible 
promoter, in a p53 heterozygous background, a pathway mutated in approximately 40% of 
the human GBM 14. We induced tumors using HRasV12 that has not been itself directly 
found mutated in GBM. However, its pathway is up regulated through EGFR and PDGFR 
amplifications or NF1 mutations214, and RAS carrying lentivirus generated GBM like 
lesion in mice215. To date, our data are very preliminary but still meaningful. In fact, we 
obtained tumors from both PRDM1 competent and KO background (see Appendix II), but 
the extent of GBM penetrance and the preliminary analyses of the lesions suggest a 
divergence with former literature: PRDM1 seems to be required for tumor initiation, and 
thus may act as an oncogene in GBM. 
This is certainly quite preliminary evidence, and we stress a cautionary note here. 
Nevertheless, the positive role for PRDM1 in neural stem cells self-renewal, is indeed 
compatible with our preliminary findings in GBM. It is also worth mentioning that a 
PRDM1 target gene in NT2-D1, which is also de-regulated in PRDM1 KO NSCs, has been 
recently found mutated in human GBM. It is the case of the H3f3a gene216-218. This gene, 
which codifies for the replication independent histone variant H3.3, seems to influence the 
epigenetic pattern of the cancer cells that show a widespread hypomethylation, possibly 
having a tumor suppressive function. Notably, in human GBM it inversely correlates with 
PRDM1, which could underpin a functional relationship. We are currently characterizing 
by histology (neo-angiogenesis, necrosis, mitotic activity) and immunohistochemistry 
(PRDM1, nestin and other markers to characterize cancer cells expression profile) the 
generated tumors. Furthermore we are in the process of enlarging our cohort of mice in 
order to get statistically significant information about the role of PRDM1 in GBM. If our 
analyses will confirm that functional PRDM1 is required in our spontaneous mouse model 
of GBM, we would proceed to a more in depth mechanistical dissection. 
	   88	  
 
In conclusion, my study led to the elucidation of PRDM1 target gene regulation, 
highlighting a role for PRDM1 in stable and heritable gene silencing during differentiation, 
and provides a resource for further mechanistical studies. Most notably however, the 
analysis of PRDM1 regulatory network led us to investigate an exciting new hypothesis: 
the positive regulation for PRDM1 of normal and cancer stem cell self renewal. 
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differentiation. Accordingly with expression data, the promoter 
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differentiation.  
	   99	  
 
